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ABSTRACT 
The effect of nifedipine saturation solubility in several cosolvent systems on 
nifedipine permeation through hairless mouse skin is evaluated. The effects of patch 
components is measured by (1) identifying those factors which significantly affect the 
permeation of nifedipine and (2) selecting settings for these factors which optimize 
flux and lag times. Of particular interest is the application of solubility theory toward 
the estimation of theoretical partition coefficients which were, it turn, useful in 
predicting the effect of donor composition on nifedipine permeation. 
A stoichiometric approach was taken to examine the influence of permeation 
enhancers on skin permeability of this calcium channel blocker. Inherent in this 
approach is that a change in one component requires collateral change in the next; a 
deficiency best handled by an experimental design of the mixture type. The ultimate 
objective was to apply regression techniques to interpret, on a molar basis, the data 
obtained from in vitro permeation experiments. The model obtained was employed 
to: (I) identify both the magnitude and significance of synergism between formulation 
components and (2) optimize the desired response. Data from these inquiries have 
contributed toward the rational selection of components in a viable transdermal dosage 
form. 
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PREFACE 
This body of work represents our observations, from conception to prototype, 
regarding the formulation of a poorly water soluble drug as a transdermal dosage 
form. Since the scope of the project was is unusually broad , we divide the main body 
of the dissertation into a general introduction followed by three chapters that address 
the issues of solubility, penetration enhancement and optimization. 
The dissertation is best envisioned as proceeding chronologically through three 
distinct phases. Section I serves to introduce the interrelationship of several physical 
and chemical properties, particularly solubility phenomenon, on the permeation of a 
hydrophobic drug, nifedipine, through hairless mouse skin in vitro. Portions of this 
material have been presented at the 18th Symposium of the Controlled Release 
Society, Orlando, Florida, July 1992. A detailed investigation of representatives from 
several classes of penetration enhancers are presented. The final section documents 
the optimization of a proposed transdermal patch. Appendix A contains the source 
code used to process the data. Appendix B is a general discussion of the 
requirements of the statistical design of mixture problems. Appendix C contains 
important experimental data such as the screening procedures used to determine the 
applicability of various components of the proposed transdermal dosage form. Finally, 
Appendix D addresses suggestions for future work. 
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( SECTION I 
GENERAL INTRODUCTION 
Rational for transdermal dosage forms - The potential of skin as a site of 
administration for systemically active drugs is evidenced by several commercially 
successful transdermal delivery systems (TDS). The drug delivery market was worth 
$8 billion in 1988; of this transdermal systems constituted $324 million in 1988 and is 
expected to reach $1 billion by 1993. 1 Since the early 1980's, several innovative 
pharmaceutical products have demonstrated the merits of delivering therapeutic agents 
through the skin. 2 Optimally designed transdermal dosage forms release drug in vivo 
according to pharmacokinetical ly rational rates so that concentrations are maintained 
within therapeutically desirable ranges. Drugs poorly available by the oral route may 
achieve therapeutic concentrations since drugs absorbed percutaneously are not subject 
to hepatic first pass metabolism. The transdermal route of administration may 
increase compliance by minimizing the inconvenience of remedication . This is a 
decided advantage in conditions e.g. hypertension where the effect of the disease is 
often sublime. The net result is a sustained, reliable, extended duration of drug 
action similar to an intravenous infusion without the many disincentives associated 
with the intravenous route of administration. 
As the concepts underlying drug delivery system design becomes clearer3•4• 5 " 6 
the potential of skin as a site of administration for systemically active drugs is being 
realized . Unfortunately , the transdermal route of adminjstration cannot be employed 
( for a large number of drugs and the problems that limit drug suitability have been 
outlined and discussed.7" 8 Briefly, the s]<jn is an efficient barrier to the ingress of 
foreign materials so that few drugs penetrate the s]<jn at rates sufficient to permit 
clinically useful transdermal application. Transdermal delivery of drugs for systemic 
effects is currently limited to nonirritating , lipophilic drugs of small molecular weight 
(less than 1000 daltons) and high potency (less than 21 mg per day) that enter the s]<jn 
by passive diffusion. Of the several layers of epidermis, the stratum comeum is 
generally recognized as the primary barrier to transdermal diffusion. The 
contribution of the stratum comeum to overall diffusional resistance tends to be larger 
for molecules of low molecular weight and lipophilicity.9 Formulations and 
methodologies which permit more than a few milligrams of drug to be delivered 
across this barrier would expand the range of candidate drugs that might be 
successfully marketed as a TDS. In the case of hydrophobic drugs it remains unclear 
how to determine a priori the optimal physicochemical properties required in a 
transdermal delivery system to best overcome the barrier function of the s]<jn. Thus, 
research efforts targeted toward maximizing penetration have unquestionably high 
clinical and financial implications. 
Choice of Penneant - With the exception of a recent publication by Diez et al' 0 , no 
comparative percutaneous absorption studies have been done to evaluate the 
dihydropyridine calcium channel antagonists as suitable TDS candidates. 
Nifedipine,(dimethyl l ,4-dihydro-2 ,6-dimethyl 
-4,(nitrophenyl)-3 ,5-pyridine dicarboxylate) is an ideal model permeant for this 
2 
research. Nifedipine is an active calcium-channel antagonist that exerts its 
pharmacological action by blocking postexcitation of ca++ ions into cardiac and 
vascular smooth muscle. Since its discovery in 1968, nifedipine has become accepted 
as a first line treatment of angina and hypertension. 11 12 Nifedipine is poorly water 
soluble and its bioavailability is low when administered orally in the solid crystalline 
form. Previous pharmacokinetic studies have shown extraordinary interindividual 
variability of the plasma levels of the drug following oral administration.'3 The 
variability in peak plasma levels (as much as 10 fold) is presumably due to the wide 
differences in oral bioavailability and first pass metabolism. The development of an 
alternative to the oral route that would bypass these significant, highly variable effects 
would offer significant advantages. Also, since transdermal administration minimizes 
pulse entry into the systemic circulation, undesirable side effects associated with 
unnecessarily high plasma levels of drug may be avoided. 
The average steady state plasma concentration of nifedipine, following an 
average oral daily dose of 30mg per day , is 47 (± 20) ng/ml. 14 Clinical studies have 
shown that the hypotensive effect as well as the untoward side effects are correlated 
with the plasma nifedipine concentration." When the plasma concentration of 
nifedipine increases rapidly, there is a marked increase in heart rate and little effect 
on blood pressure. Conversely, this undesirable situation is reversed when 
administered by slow intravenous infusion or sustained release tablet. 16 Transient, 
high plasma levels observed following oral administration of conventional capsules 
may vary by tenfold and increase the likelihood of undesirable high hemodynamic 
3 
effects. 17 An important feature of transdermal delivery systems is that they permit 
sustained, constant drug levels over a day or more. The transdermal route is also 
appealing since it can provide a zero-order rate of drug delivery, reduce problems 
associated with the aforementioned side effects and thereby improve patient 
compliance. The success of the Estraderm TM patch is evidence for the real need for 
the controlled delivery of drugs that undergo significant first pass effect. Transdermal 
estradiol relieves postmenopausal symptoms with one-tenth the amount of an oral dose 
of estrogen because the hormone enters the bloodstream directly, thus avoiding 
first-pass liver metabolism." Excessive estrogen levels (and side effects) are reduced 
when the drug is administered by a TDS. Nitroglycerin, the mainstay of anginal 
therapy, has enjoyed wide acceptance in patch form since once-a-day application 
contributes significantly towards patient compliance and avoids the large fluctuations 
in plasma levels following the oral administration. Finally, an important argument in 
favor of nifedipine is that the constant delivery of nifedipine is not thought to lead to 
the estabEshment of tolerance as seen with nitroglycerin. 19 
Following oral administration as a soft elastic gelatin capsule, nifedipine is 
completely absorbed with an absorption half life of 4 hours . Following intravenous 
administration, the drug is rapidly cleared from the plasma. When administered 
orally, nifedipine undergoes significant, variable first pass metabolism resulting in 
cmax values between 40-200 ng/ml and an absolute bioavailability of 45% to 68%. 20 
Binding of nifedipine to plasma protein is concentration dependent and ranges from 
92-98%. The drug appears to distribute in a volume slightly larger than total body 
4 
water. The elimination half life of 2 to 3 hours necessitates administration at intervals 
of every four to six hours. 
Convenient once a day dosage regimens are highly desirable in general, and 
especially for the treatment of asymptomatic diseases such as hypertension. 
Shortcomings associated with its rapid elimination following oral administration 
prompted the development of innovative drug delivery systems capable of zero-order 
drug delivery that prolong pharmacologic activity over a 24 hour period. 21 22 The 
Pfizer Procardia XL™ tablet utilizes OROSTM technology to deliver the daily 
nifedipine requirement over a 24 hour period .23 However, the bioavailability of the 
Pfizer extended-release tablet is reduced by 55-65 % of that achieved with the same 
doses administered by conventional soft gelatin capsules. Following multiple doses, 
oral bioavailability from the extended-release tablet is approximately 75-86% of that 
achieved with the same doses administered by conventional capsules. 24 Thus, more 
than twice the clinically useful amount of nifedipine is unnecessarily ingested on a 
chronic basis in order to maintain plasma levels in the therapeutic range. 
The theoretical transdermal daily dose equivalent to the minimum oral daily 
dose of 30mg, adjusted for a bioavailability factor of 0.6, is 13 mg. The results 
reported by Diez, et al. permit only 1 mg of nifedipine to be delivered transdermally 
over 24 hours under steady state conditions. When considered in light of an average 
nifedipine elimination clearance of 83 liters/hour, their optimum flux values translate 
to a predicted steady state plasma level of only 0.53 ng/ml, far short of the target 
therapeutic plasma concentration of 6-51 ng/ml. 
5 
Physicochemical properties of the permeant - Knowledge of the permeant's 
molecular structure, physicochemical properties, physicochemical compatibility and 
stability proft!es are the initial key considerations in selecting a probe. Several 
guidelines which correlate the physicochemical properties of drugs with their ease of 
skin penetration have become apparent. 25•26·&27 In general, lipid-like molecules are 
more easily delivered through the skin than are hydrophilic ones; polar substances are 
not as well absorbed as nonpolar ones; and organic liquids are better absorbed than 
solids. For the purpose of comparison, Table I li sts some of the salient 
physicochemical properties of various drugs that have been successfully delivered by 
the transdermal route of administration. Molecules like nifedipine which have 
proportionately higher lipid solubility, low melting point and low molecular weight 
should permeate the skin at greater rates. Nifedipine's molecular weight is similar to 
that of fentanyl, another drug commercially available as a transdermal dosage form . 
Nifedipine, like estradiol, has a relatively high melting point. All three drugs are 
classified as "extremely lipophilic", as demonstrated by their n-octanol:water partition 
coefficient. Of the drugs li sted, the steroids bear the best overall similarity and 
strategies used to enhance their penetration theoretically should apply equally well to 
nifedipine. 
Nifedipine is compatible with many pharmaceutically useful solvents, 
thermostable, and nonhygroscopic. Owing to the extreme low basicity of the 
dihydropyridine nitrogen it is not possible to obtain stable salts with acids. 
6 
Table I. Physicochemical properties of various drugs delivered by the transdermal route 
of administration. 
DRUG M.W. T., ti.Hr c, Log[P]' 
estradiol 272.4 176 *** 0.002 3.9 (2.3) 
fentanyl 336.5 83 *** 0.01-75 2.9 
hydrocortisone 363 .5 218 8. 1 0.389 1.6 (-0.2) 
metronidawle 171.2 159 *** 8.5 0.85 
nicotine 162.2 liq 9.4 10-50 1.17 
nifedipine 346.3 173 9.09 0.006 3.1 
progesterone 314.5 121 *** 0.009 3.9 
salicylic acid 138. 1 157 141 2.2 1.8 (1.2) 
testosterone 288.4 155 6.2 0.023 3.9 (3.3) 
theophylline 180.2 270 7.1 8.3 -0.7 (-2.1) 
Key: M.W. =molecular weight in daltons, T .. =melting point in °C, t.H, in 
kilocalories per mole, C, in milligrams per mililiter, 'Log[P] = octanol/water 
partition from Hansch and Leo, 1979 (in parentheses are isopropyl myristate/water 
partition coefficients from Surber et a128) . References unless otherwise noted: 
estradiol29 fentanyl30 31 32 hydrocortisone33 metronidazole34 nicotine" 36 progester~ne37 , salicylic a~id, testosterone38'. theophylline39 • ' ' 
7 
( Since the rate of nifedipine absorption from the gastrointestinal tract is independent of 
pH over the range of 1.2-7.S the effect of pH on skin permeation would probably be 
negligible. Nifedipine is thermostable and nonhygroscopic. Methanolic solutions 
stored at room temperature for 6 months have displayed no detectable decomposition . 
There is no influence of pH (2-12) and ionic strength on stability. It is extremely 
sensitive to light below 450 nm. The major metabolite, a nitropyridine, formed by 
enzymatic oxidation is identical to that formed by photodegradation under visible 
light. High Pressure Liquid Chromatography (HPLC) provided a straightforward, 
validated, stability-indicating analytical method of quantitatively measuring nifedipine 
and its primary breakdown products in vitro40 and in vivo.41 42 
In summary, having considered the physical characteristics of the drug and 
proposed TDS, it appears that the physical, chemical and pharmacokinetic attributes 
of nifedipine conform with those required of a drug candidate for transdermal delivery 
system development. 
Solubility theory - The solubi lity of a drug in one or more components of a 
pharmaceutical dosage form is valuable information which can be used to characterize 
its behavior. This is especially true of topical dosage forms where the solubility of 
drug can be related to dissolution rate, thermodynamic activity, vehicle release rate, 
and apparent permeation rates . Transdermal delivery is a diffusion process driven by 
the establishment of a thermodynamic activity gradient of diffusant within the skin. 
When a drug is applied topically, it diffuses passively out of its carrier vehicle into 
the surface tissue of the skin. The movement continues through the stratum corneum 
8 
and into the viable epidermis and dermis with the gradient terminating at the upper 
reaches of the microcirculation of the skin in the dermal layer. The fundamental 
equation describing diffusion in membranes such as skin is Fick's First Law. For the 
steady state case, the amount M of material flowing through a unit cross section, S, 
of a barrier in unit time, t, is known as the flux , J, 
The flux in tum is proportional to the concentration gradient, dC/dx: 
J - DdC 
dx 
(1) 
(2) 
in which D is the diffusion coefficient of a penetrant , C is its concentration, and x is 
the distance of movement perpendicular to the barrier. When donor and receptor 
compartments are separated by a semipermeable membrane of cross-sectional area S 
and thickness h, and the concentrations of the diffusant in the membrane in the donor 
and receptor sides are C, and C2, respectively, then equation (I) may be rewritten 
dM 
dt 
c -c D(-1_2) 
h 
The values of C1 and C2 within the membrane are difficult to determine 
(3) 
experimentally but can be approximated by the partition coefficient, K, multiplied by 
the concentration c. on the donor side or C, on the receiver side of the membrane 
9 
dM C[C, 
J = - = DSK(--) = PSC dt h d 
(4) 
for which, under sink conditions, C, "" 0. Thus, for a fixed surface area, the 
diffusion of permeant from donor to receptor is proportional to a gradient in 
thermodynamic activity. If the vehicle in no way changes the properties of the 
membrane (i.e., D and K remain constant) nor does the vehicle codiffuse with the 
drug then P=DK/h is a constant and equation (4) implies that an increase in the 
thermodynamic activity of a species in solution should be accompanied by an increase 
in permeability. While the activity of the permeant will vary according to the 
composition of solvent(s) used in the donor medium , it may be held constant for the 
duration of an experiment for a given donor by using a saturated solution in the 
presence of excess solid drug . 
Many have recognized that intrinsic solvent effects significantly affect drug 
transport across the stratum corneum and underlying epidermal membranes43 and that 
variation in vehicle composition often has a marked effect on the release of drug from 
the dosage form. 44 However, for those cases in which P=DK/h is a constant, 
enhancement of transdermal delivery by maximizing thermodynamic potential has 
been achieved with volatile and nonvolatile mixtures to enhance "the escaping 
tendency" of drug from a formulation by creating supersaturated conditions. 45 If 
thermodynamic activity of a species in solution is increased, diffusivity should 
increase and equilibrium saturation solubility (which is a reflection of activity) should 
provide a measure of permeability. Accordingly, if the rate of delivery is directly 
lO 
( dependent on the amount of drug in the donor then vehicle composition should have 
significant impact on the flux of drug through the skin by virtue of its inherent ability 
to solubilize the drug . Twist and Zatz observed the diffusion of parabens through 
silicone from a spectrum of polyol-water cosolvents and concluded that permeation is 
a function of permeant activity. 46 
Cosolvent mixtures can be combined to yield vehicles of variable polarity and 
are routinely used as aids to solubilize drugs in aqueous vehicles. Manipulation of 
solubility viz judicious choice of excipients has contributed to the successful 
marketing of two transdermal products. Isopropyl palmitate and isopropyl myristate 
are used as cosolvents to enhance the solubility of nitroglycerin in the polymer matrix 
type transdermal systems. The principle use of ethanol in the Estraderm patch is to 
enhance the solubility of 17-6-estradiol in the reservoir compartment of the device. 
The Duragesic patch also incorporates ethanol. Selection of the appropriate cosolvent 
system can maximize the activity, hence its flux yet minimize the potential for 
precipitation which may result following application. In practice it is difficult to 
distinguish whether flux enhancement is due to the vehicle effect on the skin to 
permeant solubility or a combination of the two. Nevertheless, prediction of 
solubility may be a useful initial tool in the design of TDS. 
In general, a compound dissolves far easier in a solvent possessing related 
functional groups than in one of a completely different nature47 . Stated another way, 
the best solvent for a particular solute is the one that most closely matches its 
polarity. While various qualitative generalizations based on molecular structure are 
II 
available, a quantitative method would be more useful. Kier"' has proposed a 
numerical index that ranks solvents according to their polarity that can be quickly 
calculated, does not depend on the availability of the actual molecule, and permits 
prediction of the polarity of solvent or cosolvent mixtures. In the method of 
coincidence, the solubility of the solute in several solvents is plotted as a function of 
either dielectric constant or solubility parameter of solvent, whereupon the value in 
question is assumed to be equal to the corresponding value of the solvents in which it 
has the greatest solubility. The latter method is well accepted and has been employed 
to evaluate the solubility parameter of nifedipine. 
Solubility parameter - The solubility parameter of solute (0,) and solvent (o 1) was 
proposed by Hildebrand in an attempt to quantitate the effect of solute-solvent 
interactions on the solubility of solutes in solvents. It is defined as the square root of 
the cohesive energy density (CED), a fundamental thermodynamic parameter that 
allows one to estimate several thermodynamic properties of solutions.49 The CED is 
the net work expended by the removal of a solute molecule from the solid plus that 
expended through the opening of a 'hole' in the solvent minus that realized from the 
insertion of the solute molecule into this hole. The cohesive energy density itself is 
defined as the ratio of the energy of vaporization to the molar volume, the latter of 
which is often difficult to verify experimentally. Unlike other measures of polarity, 
the solubility parameter describes the physical size and strength of the intermolecular 
attractive fields. Therefore, they lend themselves to predictable mechanical 
explanations of intermolecular phenomena. In addition to its importance in the theory 
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of solutions, the solubility parameter has been shown to be connected to other 
physical properties such as surface tension, wettability, boiling points, glass transition 
temperatures of polymers, the strength of materials and is used to estimate the 
miscibility of multi-component mixtures. Thus the ability to estimate the solubility 
parameter can often be an extremely useful tool that is applicable to a diverse number 
of practical problems. According to the Hildebrand solubility parameter approach, 
two liquids are miscible if their solubility parameters differ by no more than 3-4 
units . Remarkable combinations of non-solvents have been produced which have poor 
solvent strength individually while in combination exhibit good solvent strength. This 
synergism is displayed by the classic ethyl ether:ethanol {li=7.4 : 12.6) solvent 
combination used to solubilize nitrocellulose (Ii= 11.3). The robust nature of this 
approach lends itself to the problem of predicting permeant activity in the donor. 
Consequently, our efforts have been directed towards using the solubility parameter to 
predict percutaneous flux of nifedipine. 
We employ the Hildebrand approach50 to obtain the logarithm of the ideal mole 
V2<l>~{o1 - li 2)2 
2.3RT 
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(5) 
(6) 
where X2 is the mole fraction solubility of nifedipine at temperature T, ,.H, is the heat 
of fusion of the solute at its melting point T"' , and 'Yi is the activity coefficient of the 
drug in the vehjcle. The first part of the right-hand side of equation (5) gives the 
ideal solubility, whereas the second part, log 1'2> gives the contribution of the solute-
solvent interactions to the deviations of the measured solubility, X,, from the ideal 
solubility. Regular solution theory describes the activity coefficient of the drug in the 
vehicle, given by equation (6), where 0, is the solubility parameter of N, o1 is the 
solubility parameter of the vehicle, V2 is the molar volume of N, R is the gas constant 
and Tis absolute temperature. The volume fraction of the solvent, 4' 1, is calculated 
from51 
(7) 
The main limitation has been that the solubility parameter concept is strictly 
applicable only to nonpolar systems where dispersion forces predominate. Other 
forces exerted by intermolecular interactions in liquids with similar solubility 
parameter may result in very different solubility profiles. This is due, in part, to 
differences in the three intermolecular forces commonly referred to as the London, 
Keesom and Hydrogen bonding attractions. Hanson and Beerblower52 partitioned the 
cohesive energies into three terms: od is the dispersion forces observed in nonpolar, 
hydrocarbon mixtures, 00 reflects dipole-dipole interactions or 'orientation' forces 
between molecules e.g. , acetone, and o. describes the acid-base character associated 
with all varieties of strong donor-acceptor interaction between solute and solvent. 
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This third term is not restricted to hydrogen bonding. The total cohesive energy 
density, AE/V, for a species may be partitioned into contributions from dispersion 
forces , dipolar interactions, and hydrogen bonding: 
AE 
v 
(8) 
(9) 
AEv is the energy of vaporization of a liquid , AH" its enthalpy of vaporization, R the 
gas constant, T is the absolute temperature, and V is the liquid molar volume. The 
quantity o is the total solubility parameter and o2 is the cohesive energy density for a 
solvent or solute allowing equation (8) to be rewritten as 
(10) 
The dispersion parameter, o,, is obtained from data for the compound's 
homomorph, defined as a saturated hydrocarbon having essentially the same chemical 
structure, size, and shape as those of the polar compound. The polar parameter, o., 
was calculated using a modified equation from Bottcher: 
12108 E-1 ( 2 2) 2 
-- -- no+ µ 
V2 E+n'i, 
IS 
(11) 
&2 = 12108 €-l ( 2 2) 2 
P --2- ---2 no+ µ 
V c+n0 
The hydrogen bond parameter for a hydroxyl compound is obtained from 
(11) 
(12) 
where t.H is an average enthalpy of formation for hydrogen bonding, 4650 cal/mole, 
for each hydroxy group. The partial solubility parameters of Hansen are obtained 
from the literature" or estimated using one of several group contribution methods.54 
Solubility and partition coefficient are two factors of crucial importance to 
consider in the design and development of new dosage forms. While readily 
estimated,55 it is sometimes unfeasible or impossible to physically measure either 
property in some systems. The theoretical partition coefficient and ideal mole 
fraction solubility can be estimated using solubility parameters. Fortunately, the 
solubility parameter itself is easily and accurately estimated from a knowledge of 
molecular composition. Methods that permit the estimation of a compound's 
solubility parameter based on functional group contributions are based on the 
assumption that group increments exist which may be summed over the known 
structure of the substance. A BASIC program for the calculation of solubility 
parameters of compounds of pharmaceutical interest has been reported. 56 Values 
obtained are in good agreement with values determined experimentally. These results 
are noteworthy, given that when Hildebrand established the thermodynamic principles 
of intermolecular cohesion , it was restricted to nonpolar solutes in nonpolar solvents. 
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Of the various methods proposed for estimating the solubility parameter, we have 
chosen the method proposed by Fedors'7 for two reasons: (1) the contribution of a 
much larger number of functional groups were evaluated and (2) the method requires 
only a knowledge of the structural formula of the compound. 
The distribution of a drug between two phases, represented by the term K 
introduced in equation (4), is given in equation (13) 
Y2 log K = log-
y skin 
(13) 
Since each activity coefficient in equation (13) can be calculated from equation (6) , 
a theoretical partition coefficient can be calculated by substituting the values for the 
calculated activity coefficients into equation (13). Use of the difference between the 
solubility parameter of drug and membrane to explain differences in biological activity 
of drugs was first introduced by Mullins." Sloan used the expanded form of equation 
(13) as a means of calculating theoretical solubilities of theophylline in hairless mouse 
skin so that theoretical vehicle-membrane partition coefficients between skin and 
various polar and non polar vehicles could be estimated. 59 In a separate study, 
salicylic acid was used as a model compound to study the relationship between the 
solubility parameter of drug and membrane on transport through lipoidal 
membranes. 60 In both cases, a good fit between the theoretical partition coefficients 
and the experimentally determined permeability coefficients were obtained. The 
influence of solute solubility on flux in vivo has also been noted for estradiol. 61 We 
propose to examine the properties that seem to limit drug suitability so that the 
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rational formulation of a new generation of transdermal systems can occur. 
Penetration enhancers - Of the various layers of the skin, the stratum comeum is 
believed to pose the greatest diffusional resistance. Since diffusion through the 
stratum corneum is usually the rate limiting step, enhancement of permeability is 
usually directed toward reversibly altering the properties of the stratum corneum. 
The term "penetration enhancer" is applied to agents which reduce the diffusional 
resistance of the stratum corneum, by reversibly damaging it, or by altering its 
physicochemical nature. The previous discussion considers only the simple situation 
in which diffusion occurs in a single homogenous medium. However, skin is a 
heterogeneous multilayer tissue. The concentration gradient developed over several 
strata is analogous to an electrical circuit, either in series or in parallel, where each 
strata contributes a unique diffusional resistance. While the total resistance of the 
composite is essentially a function of the high resistance of the stratum corneum, it is 
incorrect to attribute the properties of one single layer to the individual properties of 
the composite layers. Modeling the skin in this superficial manner may give rise to 
false assumptions on how these properties may be altered. That the permeation 
process is more complex than the simple case of diffusion through the stratum 
comeum suggests and that the subdivisions of the skin should be considered 
individually. 
The partition coefficient is crucially important in promoting a high initial 
concentration of the agent within the upper strata of the epidermis. Nonpolar 
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molecules are expected to diffuse passively though the lipid domains of the stratum 
comeum intercellular space. If the intercellular transepidermal pathway transport 
mechanisms control drug passage through skin, one would expect the partioning 
behavior of the drug to influence its permeation and a correlation should exist 
between partition and permeability that, in tum, relates structure to permeant flux. In 
practice, partition coefficients based on various reference systems are often unreliable 
predictors of relative permeabilities but at least constitute a frame of reference from 
which to envision drug movement through the skin . Given the high octanol-water 
partition coefficient of nifedipine (10,000: 1) and that the solubility parameters of 
porcine skin and nifedipine are nearly identical leads to the supposition that: (I) 
nifedipine should have high affinity for and readily penetrate stratum corneum lipids 
and (2) significant resistance to nifedipine diffusion should reside in the deeper dermal 
layers. Scheuplein had calculated that a tissue-water partition coefficient of > 400 
was required before a 200 micron layer of dermis had a diffusional resistance 
comparable to that of stratum corneum 10 microns thick. 62 Indeed, our experiments 
on stripped skin have confirmed that a significant barrier to diffusion still exists even 
when the stratum corneum has been removed. Therefore, the ideal patch design 
would encompass the following functions: (1) initial high activity of drug in the patch 
creates a severe gradient forcing the drug from the patch into the epidermis; (2) 
release of enhancer(s) to alter the diffusion coefficient of the drug; and (3) release of 
cosolvent at a prescribed rate so as to modify nifedipine solubility in the lower 
epidermal and dermal layers. 
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Chemical enhancers can be grouped into two general categories: amphoteric 
molecules (such as Azone and oleic acid) and cosolvent molecules (such as 
dimethylsulfoxide, propylene glycol, and ethanol). 63 Amphoterics are thought to 
enhance permeation by increasing the diffusivity of the permeant through the stratum 
comeum, while cosolvents are used to promote the partitioning of drug in the skin 
layers. It is often difficult to distinguish from the array of possible mechanisms by 
which an ingredient may influence permeant diffusion . For example, surfactants can 
alter the kinetics of drug permeation through the skin by a direct effect on the skin 
barrier, through complexation or solubilization of the drug, by improving wetting of 
the membrane or through alteration of the permeability of skin to water. 64 65 66 
Generally, a penetration enhancer is selected based on the physicochemical 
properties of the permeant. Since lipophilic drugs are believed to penetrate the 
stratum comeum by passive diffusion though the intercellular lipids, materials (e.g . , 
oleic acid or Azone) that are known to increase the diffusivity of permeants in the 
'lipoidal' pathway should be better suited than enhancers that affect the proposed 
'polar' pathway. Alternatively, the polar pathway, proposed to account for the 
anomalous permeation of small or ionizable molecules, would seem unsuited for 
nifedipine, which is a molecule of moderate molecular weight, insignificant pKa, and 
poor water solubility. A preliminary saturation solubility profile compiled from the 
literature shows nifedipine to have affinity for solvents of moderate dipole moment 
with minimal hydrogen bonding interactions. Nifedipine appears to lie midway in the 
lipophilic-hydrophilic continuum, prohibiting generalizations regarding passage via a 
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lipoidal or polar route and, of course, the subsequent choice of enhancer. For 
permeants with poor solubility profiles, the cosolvent-type permeation enhancers have 
been successfully employed either alone or in combination. Generally, these 
enhancers exert their influence rapidly, but this influence diminishes relatively soon 
after the delivery system has been removed from the skjn. Because they penetrate the 
skjn, there may be questions regarding toxicity and irritation during chronic 
application. 
Utiljzation of enhancers to optimize transdermal delivery introduces potential 
adverse interactions between drug, enhancer, system components, and skjn. 67 
Unfortunately, it remains unclear how to best choose ideal enhancer combinations. 
An interesting approach to enhancer selection is based on the use of quantitative 
structure-activity relationships to predict the pharmacological properties of organic 
compounds. This is accomplished by the assignment of organic and inorganic values 
for a given compound depending on structural components. 68 Hori obtained 
conceptional diagrams on which classical enhancers and newer enhancers were located 
in quite different regions. What emerged was a clear relationship between 
pharmacological actions and the physicochemical properties of organic compounds. 
These studies provided an impetus for our search for appropriate enhancers, based on 
physicochemical properties , that interact in a positive synergistic manner to enhance 
nifedipine delivery. A review of materials considered in the present work now 
follows. 
Alcohols - Studies using ethanol69 and the other lower n-alkanols70 on hairless mouse 
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stratum corneum have provided no evidence of direct effects on lipid alkyl chain 
packing, mobility, and conformational order. Knutson et al71 suggested that ethanol 
functions as an effective "fluidizer" in the stratum corneum lipid bilayer on some 
locus at or near the polar head plane rather than the bilayer hydrocarbon interiors. 
Ethanol is presumed to exert its influence by swelling and softening the stratum 
corneum, thereby reducing its effectiveness as a permeation barrier. 
A reservoir-type therapeutic transdermal system using pure ethanol or ethyl 
acetate to provide constant release of estradiol are well tolerated. n The effects of 
ethanol on the adhesive strength of a variety of control membrane laminates have been 
examined.73 Alza controls a patent on ethanol as an absorption enhancer and it is 
incorporated in their Estraderm and Duragesic products. Estradiol alone cannot 
permeate the skin to produce adequate plasma levels, hence the Estraderm patch uses 
ethanol to promote the partitioning of the drug into the stratum corneum and so 
reduce this barrier's resistance to drug transport. The transport rate from a saturated 
ethanol/water donor suspension is approximately 20 times that found for aqueous 
suspensions. In the Duragesic patch, alcohol (O. lml/!Ocm2) is used to increase the 
permeability of the skin to fentanyl and to enhance the rate of drug flow through the 
rate-limiting membrane. Only a small amount of alcohol ( < 0.1 ml per 10 cm2) is 
actually released from the system during a 72-hour application period. A linear 
dependence of ethanol on drug penetration has been observed in nitroglycerin74 and 
for the ethanol-ethyl-acetate cosolvent in levonorgestrel.75 
Twist and Zatz have shown that the relative flux from a series of alcohols is 
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correlated with the amount of alcohol imbibed by polydimethylsiloxane membranes.76 
Good et al77 reasoned that because there was a good correlation between the flux of 
ethanol and estradiol, an important feature of an estradiol TDS is to control the rate 
of ethanol release which in tum would moderate the flux of the drug through the skin. 
Smith, et al,78 measured plasma estradiol levels following application of Estraderm 
patches with and without additional amounts of ethanol added over a period of one 
week. Addition of 0.6 ml of ethanol on day 3 significantly extended the mean time 
O(by 50 hours) for serum estradiol levels to return to baseline without increasing peak 
absorption. These observations are noteworthy: ethanol, a polar molecule, has 
enhancing effects on lipophilic molecules which are transported mainly through the 
lipoidal pathway and this effect is somehow linked to the rate and extent of alcohol 
uptake into the membrane. 
Propylene Glycol (PG) - PG has been shown to significantly increase the solubility of 
drugs in the stratum comeum and therefore enhance the permeability of the skin.79 
Cited as a penetration enhancer, PG also alters the release rate of steroids by its effect 
on permeant thermodynamic activity. This may be partially explained by the ability 
of PG to permeate the skin in substantial amounts. 80•81 PG may both increase and 
decrease permeation of substances and appears to aid penetration best when combined 
with surface active agents. 82 Nomura et al. 83 observed that PG was readily absorbed 
through rat skin and that PG percutaneous absorption profiles were similar to those of 
indomethacin, suggesting that PG and indomethacin penetrate together through the 
skin. Sheth et al84 reported the influence of Azone, propylene glycol and polyethylene 
23 
glycol on in vitro skin penetration of triflurothymidine. The synergistic advantage of 
multiple enhancers on estradiol permeation has been displayed by the combination of 
Azone with propylene glycol. 85 
Fatty acid & alcohols - Palmitic, oleic and linoleic acids are the major free fatty 
acids present in serum and comprise 27, 25 and 13 %, respectively, of total 
circulating, non-esterified fatty acids. 86 Long-chain fatty acids have been shown to li.:: 
effective penetration enhancers for several lipophilic molecules through hairless mouse 
skin in the presence of cosolvents. 87 Work performed in a multicenter collaboration 
established that the cis-isomer of oleic acid disrupts the "lipid fluidity" of the stratum 
corneum; the trans isomer did not demonstrate this effect. 88 This increased chain 
mobility is the hypothetical 'fluidization' of lipid bilayers thought to be responsible 
for the penetration enhancement of agents that act on the lipoidal pathway such as 
oleic acid. 89 In light of the considerable attention with regard to their effect on 
membrane permeability, the effect of long chain fatty acids and alcohols on nifedipine 
permeation was investigated. 
Objectives of the Present Study 
I. Screening studies targeted toward the identification of formulation 
components that enable the model permeant, nifedipine, to be delivered in measurable 
quantities across a semipermeable membrane. 
2. Extension of our knowledge regarding the influence of a perrneant's 
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physicochemical attributes on patch design and performance with the intent that such 
inquires may serve as a paradigm in the development of new transdermal delivery 
systems. 
3. Assess the value of using mole fraction comparisons between patch 
components using statistical designs developed for problems involving mixtures. 
4. Material selection process and compatibility studies for fabrication of a 
transdermal delivery system prototype. 
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TRANSDERMAL DELIVERY OF NIFEDIPINE: 
FEASIBILITY STUDIES BASED 
ON SOLUBILITY PARAMETERS 
33 
ABSTRACT 
The solubilities of a hydrophobic drug, nifedipine, in a diverse panel of 
solvent and cosolvent systems were determined experimentally at 25 °C. The 
observed solubilities were examined for deviations from solubilities calculated by the 
Hildebrand and Scott equation. When presented graphically, the ideal solubilities 
showed a pattern of positive deviations from ideality. Despite its low aqueous 
solubility, nifedipine solubility was maximal in semipolar, aprotic cosolvents. The 
influence of solubility in several cosolvent systems on nifedipine permeation through 
hairless mouse skin was evaluated in the four cosolvent binary systems. The 
solubilities of nifedipine were measured in four cosolvent-dimethylisosorbide 
mixtures and the theoretical skin:vehicle partition coefficients were calculated. The 
amount of nifedipine permeated at 24 hours post application from the representative 
donor systems administered as suspensions were measured across nude mouse skin ill 
vitro. For the systems studied, it was concluded that: (I) permeation is not 
exclusively under thermodynamic control; (2) nifedipine solubility is enhanced in 
moderately polar solvent systems; and (3) solubility parameter was useful in 
predicting the effect of donor composition on nifedipine permeation. 
INTRODUCTION - The stratum corneum has been characterized as a lipoidal region 
that often constitutes the primary barrier to transdermal delivery. Generally, 
]jpophilic permeants that display low polarity or poor water solubility partition more 
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readily into this region of the epidermis. While most drugs are poor candidates for 
transdermal delivery for molecular reasons, the vehicular influence on transdermal 
drug penetration is well recognized' 2 and the choice of vehicle can materially affect 
permeation rates to the extent that this route becomes a viable option. 3 The 
dihydropyridine class of calcium channel blocking agents have received attention as 
candidates for transdermal delivery' with the permeation of nicardipine5 and 
nifedipine6 shown to be strongly influenced by the thermodynamic activity of drug in 
the donor phase. 
A reliable means of flux prediction would be of great value in the screening of 
drugs and excipients. Vaughan discussed the utility of employing the solubility 
parameter early in the drug development process to facilitate vehicle selection in 
topical dosage forms. 7 Several methods of predicting skin permeation have been 
described, 8 many of which require the availability of preliminary data obtained 
following the determination of levels of radiolabelled drug in various skin layers. 
Alternatively, the percutaneous absorption of some permeants have been explained in 
terms of molecular volume, partition coefficient, solubility, or some other related 
physicochemical parameter'. 
Regular solution theory has been applied by several groups to describe the 
partitioning process in topical delivery.• Sloan and coworkers'0 used solubility 
parameters to estimate theoretical skin:vehicle partition coefficients of topical 
formulations. Their experimental design incorporated three key features. First, only 
saturated solutions of drug may be applied to the membrane to insure constant 
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thermodynamic activity . Second, the contents of the donor and receptor 
compartments are rinsed and the skin is subjected to a 24 hour washout period to 
recover residual drug and cosolvent . Third , the effect of the initial application of 
donor vehicle on intrinsic membrane properties is evaluated by a second application of 
donor after the washout period. This study focuses on solubility theory with the 
ultimate goal of characterizing interactions between drug, skin and solvent that may 
affect the skin permeability of a drug of poor water solubility. Since nifedipine 
displays many of the attributes required of a drug suitable for delivery through the 
skin, this study employs nifedipine as a model permeant to examine the relationship 
between drug and vehicle on skin permeation. This is accomplished by observing the 
effect of donor composition upon nifedipine solubility and nifedipine permeability. 
Percutaneous penetration is considered primarily a passive diffusion process 
that is driven by the difference between the thermodynamic activities of drug in the 
vehicle and the slcin . 11 If the permeation is Fickian it may be described by equation 
(1) and the driving force is the concentration differential between donor and receptor. 
c -c 
DSK(-d-') ; PSC d 
h 
Equation (1) suggests that one scheme for optimizing flux is to ensure that the 
(1) 
medicament is at its maximum thermodynamic activity within the vehicle. It has been 
shown that thermodynamic activity and chemical potential are simply a measure of 
'escaping tendency' of a drug from a vehicle and that the higher this property, the 
greater the amount of drug should partition from the vehicle into the epidermis.'2 
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Assuming all terms in the model remain constant, maximal flux should occur when 
the penetrant has achieved maximal thermodynamic activity. By definition, maximal 
activity occurs when solid drug is in equilibrium with drug dissolved in the vehicle. 
Under ideal circumstances diffusion is neither rate limited by the intrinsic dissolution 
rate or affected by the partitioning characteristics of the drug; and all vehicles that 
contain drug as a finely ground suspension also exist as a saturated solution which 
sustain constant escaping tendency for the duration of the experiment. 
METHODS 
Materials - Nifedipine, ethyl-p-amino benzoate (EPABA), propylene glycol, and fatty 
acids were purchased from Sigma Chemicals St Louis, MO 63178. Long chain 
alcohols were obtained from Janssen Chimica (Spectrum Chemical Mfg. Corp. 14422 
South San Pedro St. Gardena, CA 90248). Morpholine and its analogues (Texaco 
Chemical Company, 4800 Fournace Place Bellaire, TX 77401); dimethylisosorbide 
(IC! Specialty Chemicals , Wilmington, DE 19897); ethylene and propylene oxide 
block copolymers (BASF Chemicals, 100 Cherry Hill Road, Parsippany, NJ 07054); 
Azone (Whitby Research, 2801 Reserve Street, Richmond, VA 23261); Volpols and 
Polychols (Croda Inc, 183 Madison Avenue, New York, NY 10016); and 
polyethylene glycols and silicones (Dow Corning) were donated by the respective 
companies. 
Preparation of Solutions - In view of the high sensitivity of nifedipine to light, all 
experiments were carried out in a darkened room illuminated by gold fluorescent 
tubes (Westinghouse FCl2T9 SW32W). All percentages are expressed on a 
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weight:weight basis unless specified otherwise. Molecular weights obtained from 
average hydrophilic chain length were used in all calculations. All weight 
determinations were performed on a Metler A 240 balance or Perkin-Elmer Model 
AD-14 microbalance. Four binary cosolvent mixtures were prepared from Volpol-3 
(VOL:DMT), nonoxynol-9 (NX9:DMI), polyethylene glycol 400 (PEG:DMI) and 
propylene glycol (PG:DMI) employing dimethylisosorbide as the secondary solvent 
present in the binary mixtures. The composition of these binary mixtures ranged 
between 0 to 100% and are expressed in terms of the mole fraction percent of the 
DMI component. 
Differential Scanning Calorimetry - The melting point and heat of fusion for 
nifedipine were obtained using a Perkin Elmer Model DSC-4 calorimeter and TADS 
software. Determinations were in triplicate using a scan rate of JO.O degrees per 
minute and a sample weight of approximately 4 milligrams in vented pans. 
Chromatographic conditions - All separations were performed on a Baseline 8 JO 
Chromatography Workstation (Dynamic Solutions Division of Millipore 2355 Portola 
Road , Ventura, CA 93003) configured as follows: a Waters Model 501 Solvent 
Delivery system, a Waters Intelligent Sample Processor Model ?JOB, and a Waters 
Model 484 Tunable Absorbance Detector set at 230 nanometers. Peak aquisition and 
integration was performed on the workstation NEC microcomputer following AID 
conversion through a SIM interface. Nifedipine concentrations were determined from 
peak areas by the external standard method using EPABA. 
A Hibar RT 250-4 LiChrosorb RP-18 (JO micron) column protected by a 
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LiChrocart RP-18 (5 micron) precolumn (EM Separations, 480 Democrat Road, 
Gibbstown, NJ 08027) was kept at 37°C in a Model CH-30 HPLC Column Heater 
(F!Atron Laboratory Systems, 510 South Worthington, Oconomowoc, WI 53066). 
An isocratic mobile phase was prepared as follows: filtration of HPLC grade 
acetonitrile, methanol and water individually through 0.45 micron teflon filters; 
measurement in a ratio of I: I :2 by volume, respectively; sonication for 20 minutes in 
a Model TIOO sonicator (National Ultrasonic Corporation, 111 Montgomery Avenue, 
Irvington, NJ.) and used at a flow rate of 1.3 ml per minute. 
Solubility studies - Cosolvent blends were prepared on a mole fraction basis. Donor 
suspensions were prepared by adding excess nifedipine to the cosolvents and agitating 
in a Fisher Versa-Bath S Model 224 at 37°C until equilibrium was obtained (generally 
72 hours). The suspensions were centrifuged at 1500 rpms for 20 minutes, 
transferred to a 3 milliliter glass luerlock syringe fitted with a 0.2 micron Milex-FG 
filter (Milipore Corp. Bedford, MA 01730). The contents were expressed into amber 
glass tubes after having discarded the first milliter of filtrate. A tarred positive 
displacement syringe (Unimetrics Corporation 1853 Raymond Ave. Anaheim, CA 
92801) was used to determine the density of the filtrate. Filtrates were diluted in 
methanol in triplicate and concentrations determined at 238 and 350 nm using a 
Hewlett-Packard 4105 Spectrophotometer. 
Penneation experiments - Hairless mouse skin was chosen as a permeability barrier 
after initial studies showed that flux across silicone (Dow-Corning) and ethylene-vinyl 
acetate (90: 10, 40 µm) copolymer (3M Corporation) was very poor. Female hairless 
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mice (26-28 grams, 8-12 weeks of age) were the progeny of four females and one 
male SKH-1 obtained from Charles River Laboratories. A separate fresh skin sample 
was used for each individual cell. Following cervical dislocation, whole thickness, 
intact skin from the ventral region was removed using blunt dissection and 
immediately placed on the diffusion cells in contact with the receptor phase. 
Four vertical diffusion cells with surface area of 4.9cm2 (Crown Glass, 
Somerville, NJ) were used for each experiment, keeping one as control. The receptor 
phases of the diffusion cells were maintained at 37 ± 0.1 °C with a circulating water 
bath. To ensure sink conditions, the receptor fluid consisted of a 6:4 (v/v) mixture of 
0.9% sodium chloride and polyethylene glycol 400 which was replaced periodically as 
needed . The diffusion cell was assembled, 18 ml of receptor solution was added, a 
reference (zero-hour) sample was taken, the nifedipine:cosolvent suspensions were 
added by weight to the donor side of the diffusion cells using a tared syringe and the 
donor chambers were occluded with Parafilm. All diffusion cell experiments were 
run using suspensions of nifedipine in the various vehicles so that the thermodynamic 
activity of nifedipine would remain constant throughout the study period. A control 
cell received the donor formulation without drug . Samples of the receptor phases (I 
ml) were tranfered to JO ml screw top test tubes to which 40 µg of EPABA had 
previously been added as a methanolic solution and evaporated to dryness, 50 µl of 
10% trichloroacetic acid and 4 ml of chloroform are added, the tubes gently agitated, 
and centrifuged at 3000 RPM for ten minutes. The aqueous supernatent is aspirated, 
the organic phase evaporated to dryness and reconstituted with I ml of mobile phase. 
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Mass balance was performed by washing the donor compartments with 10 ml 
of methanol each, taking care to remove any solid nifedipine particles and to keep the 
time of contact of methanol to a minimum (less than 3 minutes total). The methanol 
washes were combined, diluted and measured by HPLC. The receptor phase was 
changed and the skin kept in contact for 23 hours with fresh receptor fluid to allow 
any residual drug to leach out. At the end of 23 hours, the receptor phase was 
removed and analyzed. After another I hours of contact between the skin and the 
fresh receptor phase, the receptor phase was analyzed to assure that no more 
nifedipine had leached from the skin. Recoveries of approximately 90% of the 
original applied dose were achieved. To confirm that donor did not significantly alter 
barrier properties, donor was reapplied at the 48 hour mark and sampling continued 
until 72 hours. 
We have adopted the protocol described by Sloan'" to observe the effect of 
permeant solubility upon in vitro diffusion experiments in hairless mouse skin over 72 
hour periods. Application of regular solution theory to predict the partitioning 
process requires three essential features in the experimental design: (!) saturated 
solutions are applied to the skin, (2) after each initial application period, a 24 hour 
washout period is used to determine the degree of accumulation in the skin, and (3) 
after the washout period, a second application of saturated drug solution is applied to 
determine the degree of damage to the skin . 
Calculations - We assume that the properties of interest are functionally related to the 
the donor composition and that by changing the proportions of ingredients, x., the 
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properties of the donor will change also. We assume the properties of the mixture to 
be a simple linear combination of its component cosolvents, of which the solubility 
parameter, o, for n solvents is 
(2) 
The solubility parameters were obtained from the literature" or, if unavailable, 
estimated using the method proposed by Fedors12 demonstrated for nifedipine in 
Figure I. 
The three partial and the total solubility parameters for polyethylene glycol 
400 (PEG400) are taken to be 15.8, 9.1, 5.2 and 19 MPa'n, respectively. 13 An 
estimate for the solubility parameter of mouse skin is 21.5 MPa1n, based on an 
estimate of 9. 7-10 (cal/cm3)in reported for full thickness porcine skin 14 [where I 
MPa'n = 2.045 (cal/cm3) 1n)] . The solubility parameter of nifedipine is estimated in 
Figure I to be 21.94 MPa1n [i.e., 10.72 (cal/cm3) 1n]. Molar volumes are equal to the 
molecular weights divided by the densities at 20°C. The logarithm of the skin:vehicle 
partition coefficients, log PC,,,,, were calculated according to Sloan'5 by equation (3) 
(3) 
where o2 is the solubility parameter of N, o, is the solubility parameter of the vehicle, 
o, is the solubility parameter of the skin, V2 is the molar volume of N, R is the gas 
constant and T is absolute temperature. The logarithm of the ideal mole fraction 
solubility of N, log x,, is calculated from the Hildebrand Equation•• 
where X2 is the mole fraction solubility of nifedipine at temperature T, .aH, is the heat 
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E,,..,(i) vm(i) 
GROUP (cal/mol) (cm3/ mol) 
1 *-NH 2000 4.5 
2 * c 2060 -11.0 
4 * -CH3 4500 134.0 
2 * -C=O 700 -38.4 
1 *-CH= 820 -1.0 
I * -N02 3670 32.0 
l * Phenyl 7630 71.4 
2 *coo 4300 18.0 
l * 6-member 
ring 250 16.0 
Sum 25930 225.5 
o2 = (25930/225.5) 'n = 10.72 (cal/cm3) 1n 
or 
10.7 * 2.045 (MPa)1n/(cal/cm3) 1n = 
21.94 (MPa)'n 
Figure 1. Estimation of nifedipine solubility parameter by Fedor's method. 
of fusion of the solute at its melting point T"" and <I>, is the volume fraction of the 
solvent. 
Data analysis - The effect of mixture composition on permeation is compared by 
determining the average amount of nifedipine recovered in the receptor phase, V,, 
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(4) 
( after 24 hours. The 24 hour nifedipine receptor concentrations, C,,4• were averaged 
and the amount permeated at 24 hours normalized for the surface area of skin in the 
25mm diameter cell, Q24., was calculated according to equation (5): 
v, 
Q24h = c,,,, * 
- 4.9cm 2 
(5) 
and the mean Q24.-values were used to compare penetration from different solutions. 
RESULTS AND DISCUSSION 
The ultraviolet (UV) spectra of nifedipine in methanolic solution obeys Beer's 
law between 0.22 and 80 µg/ml with a sharp absorption maxima at 238 and a broad 
band between 325 to 370 nm. The nitrosopyridine and nitropyridine structures in 
Figure 2 have maxima at 280-310 and 277 nm, respectively, which is in agreement 
with literature values. 17 18 The intersection of these spectra, the isosbestic point, was 
used as the detection wavelength for quantification by UV spectroscopy. The broad 
absorption band from 325 to 370 nm is relatively immune to solvent-induced chromic 
shifts and was used when other uv-absorbers interfered at the isosbestic point. While 
the metabolic and photodecomposition products of nifedipine are resolved under the 
HPLC conditions employed , they were not detected in the receptor fluid at the assay 
minimum level of detection (0.04 µg/ml). Although the metabolic fate of nifedipine 
in skin in vivo is unknown , we assume that metabolic breakdown products are not 
produced to measurable degree in the excised skin. 
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COOCH3 
/ CH3 CH3 
CH3COO 
COOCH3 
CH3 CH3 ~ COOCH3 
CH3 CH3 
Figure 2. Structure of nifedipine and its photodecomposition products. 
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The results of the solubility determinations are presented in Figure 4. It is 
readily apparent that overall the solubility parameter is a poor predictor of solubility 
because solvents coincident with the calculated value of 21.9 MPa'n for nifedipine 
comprise a full spectrum of low to high solubilities. The apparent shortcomings 
associated with the total sol ubility parameter are resolved when the solubility data are 
compared in context with either solvent H-bonding index or hybrid solubility 
parameters. To account for the polar nature of solvents, the data have been plotted 
according to Burrell's classification of solvents19 into low, medium and high 
hydrogen-bonding capacity. Hanson and Beerblower2° partitioned the total solubility 
parameter to account for di spersion (od), dipolar (o,) and hydrogen bonding ( o,J 
intermolecular forces. Partitioned in this manner the Keesom forces, described by the 
o, term, give rise to dipole-dipole interactions or 'orientation' forces that exert a 
strong influence on nifedipine solubility. When viewed in context of Burrell's H-
index, a pattern more consistent with theory emerges. Likewise, when the saturation 
solubility of nifedipine is plotted against the three Hanson parameters data structures 
analogous to those shown in Figure 4 are apparent, the most notable of which is the 
trend that nifedipine dissolves best in solvents with high o, values. Alternatively, no 
relationship between nifedipine solubility and od was evident. Nifedipine appears to be 
a neutral compound with neither strong lipophilic nor hydrophilic character. 
Nifedipine solubility was maximal in amphiprotic (glycols, polyols, and alcohols) 
solvents that are somewhat polar (acetone, chloroform, dimethyli sosorbide or 
methylene chloride) molecules having significant dipole moment. 
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Figure 3. Ultraviolet-visible absorbance scan of nifedipine before (A) and after (B) 30 
minute exposure to ambient light. 
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The limited solubility of nifedipine may violate the assumption that diffusion is 
the rate limiting step in the permeation process. Consequently, it was important to 
determine the influence of equilibration time on the equi librium saturation solubility, 
C,. The C, of nifedipine as a function of various equilibration times presented in 
Table II show no significant dependency of dissolution on equilibration period. The 
saturation solubility of nifedipine in water is only 0.006 mg/ml and in PEG 400 it is 
99 mg/ml. The saturation solubility of nifedipine in the 25% and 40% binary 
mixtures of PEG in normal saline are reduced to 0.240 and 0.462 mg/ml, 
respectively . The influence of even moderate amounts of water results in a sharp 
decrease in nifedipine solubility in ternary mixtures of PEG:DMI:water or 
PG:DMI:water. As drug diffuses from the nonpolar environment of the epidermis 
into the hydrated layers below, the poor water solubility of nifedipine may impede its 
diffusion at the dermal:epidermal interface. 
The ideal and experimentally observed mole fraction solubilities of nifedipine 
in binary cosolvents are compared in Figure 5, Figure 6 and the quaternary systems 
in Figure 7 . Ideal mole fraction solubilities, calculated from Equation (4) consistently 
underestimate the solubilities determined experimentally which infer the existence of 
strong intermolecular attractive forces between nifedipine and cosolvent molecules. 
This nonideality, resulting from the second term of equation (4), violates the 
assumption that solute and solvent behave in a noninteracting manner and the 
extended Hildebrand method cannot be expected to apply where strong interactions 
exist. Nifedipine does not behave as an "ideal" penetrant; in neither system does the 
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maximal Q-value coincide with the partition coefficient that favors optimal movement 
from the vehicle into the skin rendering the interpretation of log PC, .• difficult. The 
predictable behavior for solvents of moderate H-bonding capacity di splayed in 
Figure 4 suggests that the Hansen partial solubility parameter approach might offer 
advantages. Unfortunately the partial parameters of the stratum corneum are not 
known at this time. 
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Figure 4. Saturation solubility (mg/ml) versus total solubility parameter (MPa)1n for 
the compounds studied. 
KEY: acetonitrile (ACN), butanol (BOH), chloroform (CF) , dichloromethane (DCM), 
diethylene glycol (DEG) , dimethyisosorbide (DMI), dimethysulfoxide (DMSO), 
ethanol (ETOH), ethyl acetate (EAC), ethylene dichloride (EDC), hexane (HEX) , 
methanol (MEOH) , methylcellosolve (MC) , mineral oil (MO) , nonoxynol-9 (N9), 
PEG-5 oleyl ether (VOLPOL), polyethylene glycol (PEG400), propylene glycol (PG), 
piperidine (PIP), propanediol (PDIOL), tetrahydrofuran (THF). 
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Table II. Effect of equilibration period on experimentally determined saturation 
solubilities of nifedipine in several solvents. 
Equilibration Period (days) 
Solvent' 0.5 1 3 7 30 
Equilibrium Saturation Solubility (mg/ ml)" 
DMI 88.44 89.75 88.15 94.33 90.18 
(1.4) (2.3) (2.0) (5.3) (2.8) 
PEG 82.57 83.20 82.97 83 .75 84.14 
(3.6) (2.3) (2.9) (1.2) (2.0) 
PG 9.2 IQ. I 11.8 9.7 10.7 
(2.4) (3.5) (2.2) (1.7) (3 .6) 
Water 0.014 0.013 0.015 0.017 0.014 
'Key: dimethylisosorbide (DMI), polyethylene glycol (PEG), propylene glycol 
(PG); •average of three determinations (± standard deviation) ; 'single 
determination; 
Further evidence of significant Keesom interaction is found in the disparity of 
partition coefficients obtained from various lipophilic phases. The partition ratio 
varies greatly depending on the material chosen to represent the lipophillic phase 
(approximately 10: I and I 0000: 1, when measured in cyclohexane-aqueous buffer and 
octanol:aqueous buffer (pH 7) systems, respectively). The disparity between the 
partition coefficient measured in octanol versus hexane may be attributed to the 
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Figure 5. Nifedipine solubility in polyethylene glycol 400:dimethylisosorbide binary 
cosolvent mixtures. 
Keesom interactions deemed present based on the pattern in the solubility results 
presented in Figure 4. Although nifedipine does not readily infiltrate environments of 
strong hydrogen bonds, there is a disti nct affinity for solvents with dipole-dipole 
intermolecular attractions. For example, in Table ITI, nifedipine has a high solubility 
in the morpholine cogenors tested. These molecules have significant dipole nature 
and suspensions of nifedipine in the morpholine derivatives all demonstrated high 
fluxes. 
The environment of the stratum comeum is primarily lipophilic in nature and it 
has been suggested that 'best' candidates for transdermal delivery are lipophilic 
molecules. Nifedipine, with neglible water solubility, a large octanol:buffer partition 
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coefficient, and a total solubility parameter matching that of the skin, appears at first 
glance to posses the prerequisite qualities of a 'good' candidate for transdermal 
therapy because of its 'lipophilic' nature. However, our solubility results clearly 
show that nifedipine appears to interact strongly with solvents primarily via Keesom 
forces which accounts for a poor solubility in lipids (hydrocarbons, fixed oils, etc.) 
and a low hexane:buffer partition coefficient. In addition, recovery studies show that 
only small amounts ( < 10%) of the total dose applied partition into and are retained 
by the excised skin. Furthermore, our results of differential scanning calorimetry 
shown in Figure 8 reveals a melting point and enthalpy of fusion of nifedipine that is 
uncharacteristically high for those compounds in Table I on page 7 generally 
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classified as lipophilic. Jn view of the many contradictions that can be ascribed to 
attempting a lipophilic-hydrophilic designation for nifedipine, a relationship between 
Table III. Solubility and diffusion from nifedipine suspended in morpholine derivatives. 
Solvent 0., c. J 
Morpholine 9.36 266 12.2 ± 2.9 
Methyl morpholine 9.49 228 14.9 ± 2.0 
Ethyl morpholine 9.33 223 9.9 ± 0.7 
Aminopropyl 
morpholine 9.22 360 5.3 ± 0.9 
KEY: oT = total solubility parameter expressed in units of (MPa)'n; C, = 
saturation solubility of nifedipine as mg/ml; J = flux as µg /h•cm2; (permeation 
results obtained over the interval = 0 to 24 hours). Results represent the mean of 
3 determinations ± standard deviation. 
log PC.,v and nifedipine skin permeability is unlikely. In the systems studied , 
prediction of drug permeability based on generalizations regarding lipophilicity of the 
donor phase relative to that of skin are inappropriate for in this case 'lipophilicity' is 
a label that fails to classify. The predominate intermolecular attractive forces in lipid-
like molecules originate from Van der Walls forces which are described by the 
dispersion hybrid parameter. The primary pathway through the stratum corneum is 
generally attributed to passive diffusion through intercellular lipids. The lack of a 
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Figure 7. Nifedipine solubility in propylene glycol, oleic acid, ethanol and 
dimethylisosorbide quaternary cosolvent mixtures. 
relationship between nifedipine solubility and solvent o, values imply minimal 
interaction between nifedipine and intercellular lipid. Likewise, partitioning of 
nifedipine into the well-hydrated dermis is predicted to be low due to the presence of 
extensive strong intermolecular hydrogen bonding. 
Table IV contains the composition and permeation results from binary systems 
constituting a broad range of solubility parameters that bracketed the point of maximal 
nifedipine solubility. When these systems were reapplied to the cells following the 
washout period, no difference was observed in the pre and post treatment Q values 
and it is assumed that their effect on the intrinsic barrier properties of the skin are 
insignificant. Highest permeability is expected at the point of maximum 
thermodynamic activity and if solubility is a reliable indicator of activity, then theory 
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Table IV. Saturation solubility in and permeability of nifedipine from binary mixtures 
prepared by the addition of propylene glycol or polyethylene glycol in 
dimethylisosorbide. 
X; 0-r c , J Nifedipine 
permeated• 
Fraction of PG in DMI 
0.00 18.5 85 .0 ± 2.5 0.25 ± 0.08 29 ±9 
0.20 20.5 81.5 ± 2.7 0.17 ± 0.71 20 ±84 
0.43 22.8 57.5 ± 0.2 1.46 ± 0.60 50 ±71 
0.70 25.6 40.5 ± 5.0 0.6 1 ±0.18 172 ±2 1 
0.87 26.0 19. 1 ± 0.4 4.45 ± 1.02 523 ±120 
0.95 27.3 9.2 ± 0.01 3.84 ± 1.46 455 ± 172 
1.00 28. 1 10.0 ± 0.6 1. 86 ± 0.76 219 ± 89 
Fraction of PEG in DMI 
0.00 18.5 85 ± 2. 5 0.25 ± 0.08 29 ±9.4 
0.05 18.7 98 ± 1.0 1.42 ± 0.23 165 ± 27 
0.13 19.1 105 ± 2.8 I.SI ± 0.15 177 ±1 8 
0.30 19.8 106±3.1 2.33 ± 0. 11 275 ±13 
0.57 21.5 99 ± 3.6 5.78 ± 3.47 680 ±408 
0.80 22 .7 92 ± 2.8 2.55 ± 0.87 300 ±102 
1.00 23 .8 85 ± 1.5 0.09 ± 0.02 10 ±2 
KEY: X;=mole fraction of PG or PEG in DMI; o = solubility parameter 
expressed in units of (MPa) 'n; C, = saturation solubi lity of nifedipine in 
mg/ml; J = flux, in units of µg/h•cm2 ·cumulative amount of nifedipine 
in µg permeated over a 24 hour period (permeation results obtained over 
the interval = 0 to 24 hours). Results represent the mean of 3 
determinations ± one standard deviation. 
suggests that maximum solubil ity should occur when the solubi lity parameter of solute 
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and solvent are equal. If permeation is mosUy controlled by thermodynamic activity 
and if solubility measurements are a reliable indicator of activity, we would expect all 
PEG:DMI binary mixtures to yield equal permeation rates, which was clearly not the 
case. These results illustrate a general lack of usefulness of C, values in predicting 
skin permeation. The premise that flux is directly proportional to activity is an 
oversimplification that ignores the partitioning behavior of the permeant. While high 
concentrations of permeant in the donor phase relative to skin should promote high 
diffusion rates, equation (!)predicts that maximal flux should be achieved when the 
product of drug concentration in the vehicle, C" and PC,,, is optimal so that 
permeation is as much a function of the skin:vehicle partition coefficient. 
Equation (2) and its extensions have been successfully applied to predict the 
effect of vehicle on salicylic acid 15 and 5-fluorouraci121 delivery through mouse skin. 
Figure 9 summarizes the relationship between the theoretical skin vehicle partition 
coefficient, log PC.,,_, and the total amount of nifedipine permeated in the 24 hour 
study period, Q2,., for the PEG:DMI binary systems. The data for the PG:DMI 
binary systems are treated in a similar manner in Figure IO. Fluxes were inversely 
dependent on drug solubility in the vehicles with minimum fluxes corresponding to 
the point where o2 = o1 as predicted by equation (3). Likewise, in a study of the 
permeation of estradiol from varied concentrations of PEG 400, Valia and Chien22 
found that drug permeation rates decreased as the PEG level increased (i.e. , estradiol 
solubility in donor increases). The solubility of nifedipine is approximately constant 
in the PEG:DMI binary systems. The modest permeation rates from PEG:DMI 
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systems did not differ significantly (p=0.05) due to the high variability in the data. 
The trend for PG:DMI binary cosolvent mixtures of low solubility (high %PG) to 
display higher fluxes is also consistent with equation (3). The corollary between the 
works cited and our results suggests that drug solubility in the donor is itself a poor 
indicator of permeation. Apparently , an optimal point for penetration, corresponding 
to the product of Cv and PC,_., exists after which drug is less easily released from 
donor vehicles displaying high nifedipine solubilities. 
Khalil and Martin23 showed that the rate of transfer of salicylic acid from one 
phase to a second phase was directly dependent on the differences between the 
solubility parameter of the solute and the two phases . Furthermore, the closer the 
solubility paran1eter of salicylic acid was to that of the membrane, the faster was the 
rate of transfer of acid. The solubility parameters of DMI, nifedipine, porcine 
stratum corneum, and propylene glycol are 18.4, 20.5, 20.5, and 28.6 MPa112, 
respectively. If large differences in the solubility parameter between permeant and 
donor accelerate diffusion, better fluxes are predicted from binary mixtures high in 
PG and low DMI. The results presented in Figure 10 are consistent with these 
predictions. Permeation was fourfold greater from all PG:DMI formulations (o = 18-
29) compared to PEG:DMI formulations (o = 18-25). 
This discussion has considered the diffusion exclusively from a static 
perspective that gives rise to experimental observation not compatible with that 
anticipated from theory. However, when considered dynamically, predicted shifts in 
o., X2, and PC.,v caused by codiffusion of the DMI and PG components explain these 
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inconsistencies rather well . If nifedipine flux is dependent on the establishment of a 
hypothetical cosolvent gradient within the dermis , it would be expected to be transient 
and reversible in nature. Small amounts of DMI could transiently alter the 
hydrophilic layers, functioning as a bolus to introduce nifedipine into the skin. A 
rapid depletion of the OM component would explain why amount of drug permeated 
versus time profiles for systems in Figure 9 high in PEG (which does not traverse the 
skin yet has comparable solvent strength for N) have low Q2,. values. 
A further assumption in this scheme is that the vehicle should in no way alter 
the intrinsic properties of the skin. This discussion, based entirely on the 
presumption of static conditions, assumes that o, remains constant and disregards the 
codiffusion of vehicle into and moisture out of the skin. Other studies with 
hydrophobic drugs reveal that a complex interplay among drug, solvent, and skin 
exists in which linkage between drug and solvent permeation has unpredictable net 
results on permeation, illustrating the necessity for the measurement of the concurrent 
transport solvent levels. 24 OM! and PG are well absorbed through the skin and it is 
quite possible that at steady state, a gradient of cosolvent exists down through the 
various skin regions. Good et al.25 observed !I correlation between the flux of ethanol 
and estradiol. While there was no correlation between skin permeability and 
solubility in the vehicle, estradiol flux was linked to ethanol flux. Mollgaard and 
Hoelgaard26 measured the simultaneous skin permeation of estradiol, metronidazole, 
and propylene glycol and found that the accelerant properties were linked to ease of 
solvent penetration. 
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amount permeated over 24 hours and solubility parameter for PEG:DMI binary 
mixtures. 
Gross observations, using capillary tube measurements of the height of PG and 
DMI levels in the donor compartment, reveal that both solvents readily permeate the 
skin. If donor composition changes over the study period, so must donor solubility 
parameter and the calculated partition coefficients. For the PG:DMI systems (and, to 
some degree, the PEG:DMI systems) following application of the donor suspension, 
formulations with higher percentages of DMI initially have relatively large differences 
between the amount of drug in the skin and vehicle ( i.e., high C,,-C, values), creating 
a concentration grad ient for movement from vehicle into skin. With time, DMI and, 
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to a lesser extent, PG codiffuse through the skin which decreases the ratio of DMI 
relative to PG in the vehicle, lowering drug saturation solubility in the donor. 
Codiffusion of solvent with drug would alter the PC,.v in a way that favors higher 
permeation rates for formulations from which all DMI is penetrated in the study 
period. Better flux values were in fact observed in the OM-poor PG:DM 
formulations. Based on what is known about the epidermal and dermal layers and 
the physicochemical properties of the drug and cosolvent, it is tempting to assign a 
linkage between drug and solvent movement. The precise information regarding the 
rate and extent of DMI movement through the skin necessary for this type of analysis 
is not available at this time. 
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In summary, the transdermal permeation of nifedipine was examined in terms 
of its solubility profile. Although thermodynamic diffusant activity was a poor 
predictor of nifedipine permeability, it was possible to predict in a relative manner 
permeation response based on the initial donor solubility parameter. These results 
support the hypothesis that a linkage between nifedipine and vehicle codiffusion may 
exist and further studies to establish the nature of this dependency are underway. 
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APPLICATION OF SOLUBILITY THEORY 
TO COMPONENT SELECTION 
OF A TRANSDERMAL DELIVERY SYSTEM 
FOR NIFEDIPINE 
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Abstract 
In vitro experiments using suspensions of nifedipine (N) in mixtures of 
solvents were applied to fresh excised hairless mouse skin. The ability of penetration 
enhancer: solvent combinations of homologous members of alcohols and alkanoic acids 
in combination with Azone and isopropyl myristate to accelerate delivery rates of 
nifedipine was evaluated. Many of the alkanoic acids had a beneficial effect on 
permeation that was intensified in the presence of vehicles which readily pass the 
epidermis. Four factors - propylene glycol (PG), oleic acid (OA), ethanol (ET) and 
dimethylisosorbide (DM) - strongly affected nifedipine permeation. The positive 
synergistic effects obtained by combining one or more enhancers which act directly on 
the epidermis with solvents that improve drug partitioning in the skin resulted in flux 
values fourfold higher than that required to deliver the equivalent oral daily dose. 
Mechanical stripping of the skin showed that the stratum corneum was not the sole 
source of diffusional resistance. These results suggest that it may be feasible to 
deliver clinically useful amounts of nifedipine percutaneously by the judicious choice 
of vehicle composition . 
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Introduction - Successful systems must overcome the skin's natural ability to provide 
an efficient barrier to the ingress of foreign materials. Consequently, transdermal 
delivery has been considered feasible only for drugs for which the daily dose is of the 
order of a few milligrams. 1 In the case of hydrophobic drugs it remains unclear how 
to determine a priori the optimal features required in a transdermal delivery system to 
best overcome this barrier. Since selection of components is the single most 
important decision in the design of topical drug delivery systems, information of this 
nature is crucial in the early phases of dosage form design. The pharmacokinetic 
(short elimination half-life, moderately low daily dose and chronic use) and 
pharmacological properties of nifedipine (erratic and unreliable absorption following 
oral or sublingual delivery) are well suited to transdermal delivery systems (TDS). 
The present gap in knowledge dictates a systematic inquiry of those physicochemical 
properties of both drug and vehicle that limit drug suitability so that the rational 
formulation of new generations of transdermal delivery systems can occur. 
Of the several layers of epidermis, the stratum corneum (SC) is recognized to 
be the primary barrier to transdermal diffusion . Although only IO to 15 % of the total 
SC mass is composed of lipids, these lipids largely dictate the overall skin 
permeability properties. However, the skin is a heterogenous laminate which, due to 
its composition, may offer differential influence on overall skin permeability. 
Diffusion through this heterogenous milieu can be envisioned as a series of partitions 
starting in the lipophilic environment of the stratum corneum to a hydrophilic one in 
the dermal region and the adjacent systemic circulation. The solubility parameter of 
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nifedipine and porcine stratum comeum are similar ("" IOHil), consequently, 
nifedipine should readily penetrate stratum comeum intercellular lipids. It had been 
previously determined that nifedipine (N), despite optimal thermodynamic conditions 
favoring its diffusion from donor to receptor in vitro, does not penetrate the skin at 
rates sufficient to permit clinically useful transdermal application, presumably due to 
its poor solubility in both lipophilic and hydrophilic media. 2 Solubility theory offers 
insight as to what attributes are essential in vehicle components for nifedipine. The 
solubility profile is such that further penetration into the deeper layers is not favorable 
due to the markedly poor affinity for systems structured by extensive hydrogen 
bonding. When viewed in this simplistic manner, one would expect the diffusion of a 
hydrophobic molecule to precede readily through the epidermis and diffuse poorly 
through the dermal layers. It is likely that for drugs with poor aqueous solubility 
diffusional resistance may reside in the well hydrated dermal layers so that the choice 
of enhancer would likely be much different than more soluble permeants. This study 
seeks to characterize this partitioning process in order to gain a better understanding 
of the molecular basis of permeability enhancement in percutaneous absorption. 
Methods - A series of experiments was set up using vehicles consisting of 
dimethylisosorbide' (DM) mixed with equimolar amounts of even-numbered alkanols• 
and alkanoic acids' (8-18 C). In-vitro screening was performed using the following 
' ICI Specialty Chemicals, Wilmington, DE 19897. 
•Janssen Chimica 14422 South San Pedro St Gardena, CA 90248. 
'Sigma Chemicals St Louis, MO 63178. 
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excipients: Azone," butanol, decanol , dimethylsulfoxide," dodecanol, elaidic acid, 
ethanol, isopropyl myristate,' isopropyl palmitate,' linoleic acid, linolenic acid, 
methanol , myristic acid, nonanol, oleic acid, oleyl alcohol, palmitic acid, palmitoleic 
acid, polyethylene glycols', propylene glycol,' stearic acid, and undecylenic acid. All 
cosolvent systems were prepared and measured on a molar basis. 
The saturation solubility of nifedipine in each system was determined by 
standard procedures. Unless stated otherwise, mixtures were prepared by combining 
the long chain acids and alcohols with either dimethylisosorbide or PEG 400 such that 
each contained 10.6 µmo! of enhancer. Donor formulations were prepared by adding 
a moderate (10%) excess of nifedipine to the cosolvent mixtures and agitating for 72 
hours at 37°C. The relative potencies of the various components were compared by a 
strategy discussed by Snee and Marquardt' which determines the most important 
components in a multi-component blended system. The 15 possible quaternary 
mixtures of PG, IP, OA, ET, AZ and DM were prepared so that the mole fraction of 
each component was 25% and equimolar doses of cosolvent donor formulation (6 
µmo!) were applied to the hairless mouse skin. 
In Vitro Percutaneous Penetration - Permeation data were obtained in vitro using 
vertical diffusion cells with an inside diameter of 25mm and receptor compartment 
filled with 17 ml of 40% (v/v) PEG 400 in 0.9% sodium chloride. At selected time 
intervals the receptor solution was withdrawn and immediately assayed for the drug 
•whitby Research, 2801 Reserve Street, Richmond, VA 23261. 
' Dow Coming 2020 Willard H. Dow Center Midland, MI 48674. 
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content by HPLC. Sink conditions were maintained by periodically replacing the 
receptor fluid and the amount of drug withdrawn was corrected in the calculation of 
the cumulative amount released. The membrane employed was fresh abdominal 
female hairless mouse skin (26-28 grams, 8-12 weeks of age) bred from the progeny 
of four females and one male SKH-1 obtained from Charles River Laboratories. For 
experiments on stripped skin, the permeability experiments were carried out in the 
same manner after stripping the abdominal skin 20 times with Scotch tape (3M St 
Paul, MN) prior to excision. Identification of nifedipine breakdown products and 
quantitation of nifedipine concentrations were measured by an HPLC method. 
Penetration curves were constructed by plotting the cumulative amount of 
nifedipine, Q, measured in the receptor phase against time. All plots exhibited a 
linear portion, indicative of steady state penetration, with correlation coefficients 
greater than 0.90 throughout the linear phase. Lag times were estimated by back 
extrapolation of the linear portion to the abscissa. When the permeation curve was 
well defined, linear regression analysis yielded slopes that, when divided by the area 
(4.9 cm2) yielded the steady state flux value in µg/h •cm2 • An average was computed 
for each set of replicates. 
Mass balance was performed by washing the donor compartments with JO ml 
of methanol each , taking care to remove any solid nifedipine particles and to keep the 
time of contact of methanol to a minimum (less than 3 minutes total). The methanol 
washes were combined, diluted and measured by HPLC. The receptor phase was 
changed and the skin was kept in contact for 23 hours with fresh receptor fluid to 
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allow any residual drug to leach out. At the end of 23 hours, the receptor phase was 
removed and analyzed. After another 1 hours of contact between the skin and the 
fresh receptor phase, the receptor phase was analyzed to assure that no more 
nifedipine had leached from the skin. No evidence of metabolites was detected and 
skin binding of drug was low as recoveries of approximately 90% of the original 
applied dose were achieved. 
Data analysis - Permeability coefficients were determined by dividing the fluxes 
(µg/h •cm2) by the corresponding solubility of nifedipine in that solvent (mg/cm' of 
solution). Mean flux and lag time were compared by ANOVA using Tukey's method 
at the 95 % level. 
RESULTS 
A selection of the physical and laboratory data from the solubility and 
permeation studies performed on pure alcohols (Table VI) and from donor 
suspensions of binary cosolvent systems (Table V) are presented. The permeabilities 
listed were calculated from the linear portion of the Q versus t profile 
(1) 
where P = permeability, dQ/dt = the slope of the straight portion of the penetration 
curve, A = the surface area (4.9 cm2) and C, = the equilibrium saturation 
concentration of drug in the donor phase. 
In Table VII the values of the component proportions, x;, were set equal to 
each other so that the relative effects of the components could be assessed. In many 
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Table V. Effects of alkyl chain length on skin permeation of nifedipine from binary 
mixtures containing alkanoic acids at the 10% level. 
Vehicle 0 C, J t, 
Myristic 10.4 86 0 24 
p 
Pal mi tic 10.5 139 0 24 E 
G Undecylenic 10.9 63 0 24 
Linoleic 9.8 102 II JO 
Linolenic 10.2 97 3 14 
Oleic 10.3 106 20 10 
PG Oleic 13.4 8 34 5 
Undecylenic 13.6 13 II 4 
Myristic 10.8 39.6 0 24 
D 
M Palmitic 9.8 82.3 0 24 
I Linoleic 8.8 38.7 12 I 
Oleic 9.7 34.5 15 2 
Undecylenic 9.1 24.0 0 24 
KEY: o = solubility parameter expressed in Hildebrand units; C, = saturation 
solubility of nifedipine in mg/ml; J = flux, in units of µg/h•cm2; t1 = lag time in 
hours (permeation results obtained over the interval = 0 to 24 hours). Results 
represent the mean of 3 determinations. 
cases, lag times of formulations without hydroxyl moieties were unacceptably long; 
lag times were found to respond favorably to addition of alcohols. Positive 
synergistic relationships between combinations of enhancers that modify drug 
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Table VI. Effects of alkyl chain length on skin permeability of nifedipine from 
suspensions of various alcohols at the 10 % level. 
0 c, J p 
Vehicle 
methanol 14.5 31.2 2.2 7.1 
ethanol 12.8 19.l 2.7 14.l 
butyl 11.2 15.5 0.3 1.9 
isobutyl 10.3 16.0 0.5 3.1 
octanol 10.3 8.1 0.6 7.4 
nonanol 10.5 7.7 0.8 10.4 
decanol 9.8 6.7 0.3 4.5 
dodecanol 9.1 6.0 4.2 7.0 
oleyl 8.9 7.1 2.0 27.8 
KEY: /j = solubility parameter expressed in Hildebrand unjts [l Hi! = 1 
(cal/cm3)'n]; C, = saturation solubility of nifedipine in mg/ml; J = flux, in units 
of µg/h•cm2; t1 = lag time in hours (permeation results obtained over the interval 
= 0 to 24 hours); P = JIC,. Results represent the mean of 3 determinations 
(standard deviation in parenthesis). 
solubility in skin and those that affect drug diffusivity were shown to affect nifedipine 
diffusion to improve permeation rates and lag times. In many cases, lag times of 
formulations without hydroxyl moieties were unacceptably long; lag times were found 
to respond favorably to addition of alcohols. Positive synergistic relationships 
between combinations of enhancers that modify drug solubility in skin and those that 
affect drug diffusivity were shown to affect nifedipine diffusion to achieve desired 
permeation rates and lag times. 
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Table VII. Composition, solubility, and skin permeability for quaternary cosolvent 
systems prepared by blending PG, IP, OA, AZ, ET, and DM at the 2S% mole 
fraction level. 
I I COMPONENT I I 
CODE p I 0 A E D C.' J' 
G p A z T M 
PS. l * * * * 13.0 2.3 ± 3 
PS.2 * * * * 14.1 28.l ± 4 
PS.3 * * * * 34.3 6. 1 ± 3 
PS .4 * * * * 19.3 4.S ± 1 
PS.S * * * * S7. l 70.8 ± 4 
PS.6 * * * * 19.1 120.0 ± 1 
PS.7 * * * * lS.0 ± 3 
PS .8 * * * * IS.l ± 2 
PS .9 * * * * 2.S ± 0.4 
PS . IO * * * * 28.1 ± 3 
PS. 11 * * * * NA3 NA3 
PS.12 * * * * 40.2 41.8 ± 3 
PS . 13 * * * * 69.S ± 4 
PS . 14 * * * * S.9 ± 4 
PS.IS * * * * 14.9 ± 3 
1C,=nifedipine saturation solubility concentrations expressed as mg/ ml. 2J=flux 
expressed in units of µg /h•cm2 • 'Formulation PS .11 resulted in two immiscible 
phases. 
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The histogram in Figure 11 compares enhancement potential of binary 
mixtures of equimolar (10.6 µmo!) amounts of long-chain acid homologs in DMI. 
Also shown are the effect of addition of Azone at one and ten per cent mole fraction 
level. There is a clear trend of enhanced nifedipine permeation with increasing chain 
length in the series of acids and alcohols studied. Nifedipine permeation from 
dimethylisosorbide suspensions with 10 % oleic acid was 7 fold greater relative to the 
pure base solvent . 
r:zJ No azone 
rsJ 11 azone 
E3 101 azone 
E 10 
u 
* 
.r:: 
" (Jl ~ 
O+-~-J.,L~--1,l--~~nll:J..Cl,'--.l,J..D.16.u_~o___[n;i.o...I~~~,__~~~ I I 1 T T l 
Oleic Palmitic Myristic Llnleic Llnlenic Paloleic Eladalc Nodecan 
.a-=~ 
Figure 11. Enhancement potential of binary mixtures of equimolar (10.6 µmo!) 
alkanoic acids in DMI. Also shown are the effect of addition of Azone at 1 and 10% 
mole fraction level. 
Due to the positive effects of cis-oleic acid on the percutaneous adsorption of 
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nifedipine noted in Figure 11, this acid was studied more extensively. Figure 12 
shows the amount of nifedipine permeated versus time from formulations containing 
various levels of oleic acid in PEG 400, while the results obtained from oleic acid in 
DMI-based cosolvent systems are shown in Figure 13. The in vitro diffusion 
experiments show that oleic acid in combination with DMI or PEG has a positive 
effect on penetration of nifedipine through hairless mouse skin while DMI or PEG 
alone were not effective. The results of permeation experiments resulting from 
suspensions of nifedipine in PEG or DMI containing various concentrations of oleic 
acid (I, 10, 20, 30, and 50 % w/w) indicate that optimal flux values were obtained 
with a formulation containing 20%-30% (w/w) oleic acid, enhancing nifedipine 
absorption by more than 20 fold. Repeated administration of donor at 24-hr 
confirmed that DMI and PG did not disturb the intrinsic properties of the stratum 
comeum. Although it readily passes the skin, DMI-based suspensions had poor fluxes 
over 72 hour study periods. Plots of the amount of drug penetrated versus time 
revealed that steady state was attained in less than 10 hr. 
DISCUSSION 
To gain an understanding of the mechanism of skin permeation, the effect of 
alkyl chain length of alkanols, alkanoic acids, and isopropyl esters on nifedipine skin 
permeation was investigated . Table VI shows that as the chain length increased, the 
transdermal permeation rate decreased initially and then increased as the number of 
methylene groups in the alkyl chain exceeded ten . This effect was also observed for 
two other lipophilic drugs, indomethacin and progesterone.• The increase in 
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Figure 12 . Effect of cis-oleic acid on nifedipine permeation from polyethylene glycol 
400 based donor formulations. 
permeation rates observed in donor systems in which the number of methylene groups 
in the alkyl chain exceeded six to eight has been attributed to their potential to 
irreversibly alter the barrier function of the skin. 
The poor solubility of nifedipine in lipophilic or hydrophilic vehicles makes 
the selection of an appropriate enhancer difficult. If neither classification truly applies 
to N, the ideal formulation might include enhancers of disparate actions that act in a 
positive, synergistic fashion to enhance nifedipine permeation rates. Combinations of 
enhancers having distinct yet complementary mechanism of actions were 
conceptualized by Hori. 5 Aungst et al6 showed that the effects of a variety or 
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Figure 13. Effect of cis-oleic acid on nifedipine permeation from dimethylisosorbide 
based donor formulations. 
penetration enhancers on naloxone absorption are vehicle dependent. Wotton and 
coworkers7 demonstrated that the choice of vehicle is an important factor and that PG 
is necessary for promoting the effects of Azone on the permeation of metronidazole; 
similar effects have been reported for triflurothymidine8• Comparison of Figure 12 
to Figure 13 shows clearly that the intensity of enhancer effect is highly dependent 
upon the choice of vehicle. 
Azone at levels of 1-3 %, has been shown to enhance the penetration of a 
related dihydropyridine, nicardipine, through excised abdominal skin of the hairless 
rat using pHEMA as a rate-controlling membrane.9 Previous work has shown that 
the optimum concentration of Azone varies with both drug and the formulation being 
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examined with 2-10% enhancing while excessive amounts having deleterious effects 
on permeation. 10 Sezaki et al 11 observed that as the oil:water partition coefficient 
increases, there is a tendency for penetration to decrease in skin not pretreated with 
Arone and Azone-like enhancers and noted that a time element may be involved. The 
response of nifedipine permeation to Arone is shown in Figure 14. The permeation 
of nifedipine under the influence of oleic acid and Azone are quite different, 
suggesting that there are distinct loci in the stratum comeum upon which they exert 
their effect. Neither Arone12 or PEG 13 is systemically absorbed to appreciable 
degree. Although both materials are very good solvents for nifedipine, azone, like 
PEG, had little effect on skin permeability as seen in Figure 14. When DMl or PG 
are substituted for PEG as the base solvent in the binary mixtures, permeation rate is 
magnified several fold. Since DMI and PEG share similar solubilities for nifedipine, 
the enhancement cannot be attributed to enhancement of thermodynamic activity. 
Both DMI and PG are readily absorbed when applied topically, suggesting that higher 
flux values may be linked to the ability of the solvent to penetrate and modify the 
dynamics of drug:skin partitioning. 
Experiments on stripped skin have shown that a significant barrier to diffusion 
still exists even when the stratum comeum has been removed. Figure 15 is 
particularly interesting in that stripped skin offered slightly less resistance to 
nifedipine diffusion than intact skin. Similar results have been observed for DMSO, 14 
which apparently swells the corneocytes, reducing their barrier qualities. Other 
possible mechanisms include partial extraction of lipids and protein configurational 
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Figure 14. Effect of 2% Azone on nifedipine permeation from IP:OA:ET:PG 
suspensions (n =3). 
24 
changes resulting from replacement of water by the vehicle.15 Lipophilic solutes 
which permeate readily through the stratum comeum may be rate-limited by the 
epidermal or dermal layers. In the case of nifedipine, removal of the stratum 
comeum lipids probably accelerates the movement of the PG, ET and DM 
components which results in more rapid depletion of these key components from the 
donor phase. In this way, the results of the skin stripping experiment lend further 
credence to cosolvent control. 
The data obtained suggest strongly that enhanced transport is dependent on 
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several factors. Table VIII lists, in a qualitative manner, the relative degree of effect 
on the stratum corneum, degree of systemic absorption, and relative solubility for 
nifedipine of various vehicles and their resultant fluxes. When viewed in the context 
of the skjn stripping experiments, the observations represented in Table VIII show 
maximum flux values are obtained from mixtures that both disrupt the stratum 
corneum and create conditions that favor partitioning of drug from the epidermal into 
the dermal layers. It is interesting to speculate on the source of the difference in 
shape of the Q vs t curves from OM vs PEG based binary formulations. While OM 
and PEG possess comparable C, values, the former readily permeates the skjn while 
the latter does not. Since the donor was applied as a suspension (an infinite dose 
design), the asymptotic behavior of the profiles in Figure 13 are unexpected while 
similar experiments, using PEG as the base solvent displayed in Figure 12, do not. 
The rapid depletion of the OM component from the donor would explain why Q 
versus t profiles for systems containing small amounts of OM display asymptotes well 
before supply of nifedipine in the donor system is exhausted and constitute strong 
evidence for a possible linkage of solvent:drug in the permeation process. 
For a very lipid-soluble drug, clearance from the viable tissue may replace 
diffusion through the stratum corneum as the rate limiting step in the overall process 
of percutaneous absorption. Conventional models portray the skjn beneath the patch 
as a sink for the permeating molecule. If this assumption does not hold , passage 
through the stratum corneum may no longer be the rate limiting step to permeation 
and it would be incorrect to target the stratum corneum as the barrier to diffusion. In 
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Table VID . Qualitative predictors of nifedipine permeation. 
Vehicle C, PEA Passage J 
PEG High 0 0 0 
DMI High 0 High 0 
OA 0 High 0 0 
PG 0 High High 0 
Azone High High 0 0 
OA:DMI High High High High 
KEY: C, =saturation solubility ; PEA=penetration enhancement activity; 
Passage=permeability of vehicle; .J=flux. 
such cases, patches that incorporate penetration enhancers whose actions are restricted 
to altering the barrier properties of the stratum comeum would be inferior to those 
that incorporate agents that would promote partitioning from the epidermal to the 
dermal la ye rs. 
The partition coefficient is crucially important in promoting a high initial 
concentration of the agent within the upper strata of the epidermis. Based on the 
solubility parameter of 10 (cal/cm3) 1n for porcine skin, one would expect nifedipine to 
have a high affinity for the stratum comeum. Scheuplein has calculated that a 
tissue-water partition coefficient of > 400 was required before a 200 micron layer of 
dermis had a diffusional resistance comparable to that of stratum comeum 10 microns 
thick. 16 With an octanol-water partition coefficient of 10,000: 1, a significant 
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resistance to nifedipine may well reside in the deeper dermal layers. 
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Figure 15. Optimization of PG:OA:ET:DM formulations based on the ridge analysis 
in Table XV: Permeation of nifedipine from formulation P42. l in intact and stripped 
skin. 
Notice in Table V that in a binary systems, with oleic acid added to an 
interacting (DM) or a non-interacting (PE) solvent with similar saturation solubilities 
for nifedipine, there is essentially very little difference in nifedipine permeation. 
However, when binary systems of PG and OA are compared to the DM and OA 
systems, the results are quite different. That is, systems of PG and OA (which have 
low C,-values) promoted flux to a much greater degree with shorter lag times than 
corresponding DM:OA systems of higher nifedipine saturation solubility. 
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Furthermore, although Table V and Table VII show poor results with saturated acids 
and alcohols with molecular weight near that of myristic acid, the second and third 
highest J values derive from formulations containing the isopropyl ester of myristic 
acid. IPM, like PG, did not solubilize nifedipine as well as DMI or PG, yet higher 
fluxes were achieved from these systems. This is probably due to the fact that 
nifedipine, being more soluble in the DM:OA cosolvent, prefers to remain in the 
donor compartment. 
Another plausible explanation is that PG, being much more polar than OM, 
enhances the movement of OA out of the donor, effectively "pushing" the OA into the 
skin where its effect can be exerted. This push effect is augmented by the effect of 
transpired moisture. Solubility studies in ternary mixtures of PEG:DMI:water and 
PG:DMI:water showed that the solubi lity of nifedipine is extremely sensitive to the 
presence of water. Because of the very low aqueous solubility of nifedipine, as the 
skin becomes hydrated and the donor acquires moisture the donor may form 
supersaturated solutions. Transpired moisture absorption, when calculated on basis of 
mole fraction, has a significant effect on raising the solubility parameter of the donor. 
Essentially, donors that cannot interact and sequester water molecules (higher alcohols 
and acids) should and do display a larger "push" effect. 
The asymptotic behavior of the Q versus t curves at 12-24h for some cosolvent 
blends deserves comment. All factors being equal, the maximal rate of transdermal 
transport should occur from systems of higher thermodynamic activity, that is from 
suspensions versus solutions. In Table IX the results obtained from a system 
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containing drug at 50% below and 10% above its experimentally determined 
saturation solubility show suspension and solution gave comparable permeation rates. 
Table IX. Effect of drug level on permeation: comparison of suspension versus 
solution.' 
Mole fraction percent 
PG IP AZ ET DM c: J' 
19 5 3 16 58 - 52.2 ± 12.6 
19 5 3 16 58 85.3 48.l ± 11.4 
27 8 4 22 41 - 121.8 ± 16.2 
27 8 4 22 41 90.5 100.3 ± 18.4 
KEY: 'Formulation Pl 1.G and PllC are suspensions; Pl 1.B and Pl 1.D are 
solutions (50% of saturation solubility). bConcentration values are expressed as 
mg/ml. ' Flux values are expressed in units of µg/h•cm2 • 
If saturated and subsaturated mixtures represent different levels of activity, these 
results show that thermodynamic activity is not a critical factor in these systems. If 
excess nifedipine is present and sink conditions are maintained by replenishment of 
receptor, what may account for the abrupt decrease in permeation? A plausible 
explanation is that the supply of one or more component of the cosolvent mixture has 
become exhausted. (Figure 18 on page 108 shows the curve shape following 
application of increasing donor volumes; although no significant difference in the 
slopes are discernable, the duration of steady state flux is clearly greater when the 
number of moles of cosolvent molecules is trebled) The permeation of hydrophobic 
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drugs such as nifedipine may be contingent upon the concomitant permeation of 
cosolvent. It might be necessary to incorporate significant amounts of cosolvent in 
the patch in order to maintain desired permeation rates . Thus, the previous discussion 
regarding the dependence of the shape of the Q versus t profiles to the amount of DM 
in the formulation is entirely consistent with our earlier hypothesis that the diffusion 
of nifedipine is inextricably linked to the codiffusion of solvent 
Extraction of hairless mouse skin following permeation experiments in vitro 
recover very small quantities ( < 10%) of the administered dose. Two inferences 
emerge from this observation: either the skin as a whole has poor affinity for 
nifedipine (i.e. , the solubility parameter is not 10 Hil) or that the deposition of 
nifedipine in the SC is minimal ( i.e., the skin does indeed have a high binding 
potential for nifedipine, but that it constitutes such a small percentage of the skin that 
the quantity of nifedipine that it contains is exceedingly small) . Alternatively, the 
solvent may dissolve the stratum corneum , leaving skin with very different qualities. 
This latter alternative is unlikely, since J values obtained post 24 hours following 
repeat application of donor were similar to those obtained from the steady-state 
portion of the 0-24 hours Q versus t profiles. 
The data in Table VII summarizes the intrinsic activity on nifedipine 
permeation enhancement from the 15 possible quaternary blends. Clearly, 
formulations without DM showed very poor permeation rate compared with those 
with DM present (p < 0.05). Mixtures pairing PG with DM (e.g., P5.7) displayed 
enhancement factors five times greater than those that did not. While AZ appears to 
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have little effect in formulations PS. I (PG:IP:OA:AZ) and PS.14 (PG:IP:AZ:ET), 
formulations combining AZ with DM e.g., P5.7 (PG:IP:AZ:DM) and PS.10 
(PG:AZ:ET:DM) showed enhancement activity, suggesting that DM might exert its 
effects by enhancing the activity of other enhancers. Mixtures of ET, PG and DM 
displayed overall the highest enhancement factors. The synergistic relationship among 
these three components was highest in the presence of OA (P5.6 and PS.13). A 
maximum flux of was 120.2 (± 10.3) ug/h•cm2 was observed from formulation P5.6 
consisting of PG:OA:ET:DM, each at the 25% level. In a separate set of 
experiments, the solvents listed in Table VII were applied individually as nifedipine 
suspensions to the skin. The Q versus T profiles obtained following application of 
nifedipine suspended in pure ET, IP, OA , PG , or DM showed that none individually 
possessed the necessary intrinsic activity to match the synergistic effects observed in 
mixtures of these solvents, particularly the 25:25:25:25 PG:OA:ET:DM quaternary 
mixture. These results suggest that a ternary and possibly quaternary mixture of PG, 
OA, ET or DM is required to achieve optimum fluxes from formulations employing 
these components. 
Our interpretation of these results is as follows. Given that 00 ,r "" .S", binary 
mixtures whose solubility parameter approaches that of the stratum corneum have 
higher C, values and J values should decrease. Conversely mixtures having solubility 
parameters greater than 10 have lower nifedipine solubilities, a condition which favors 
drug movement from donor into skin. This trend is observed in Table VI and 
Table VII, where .S values are associated with higher J values. Therefore, the ideal 
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patch design would encompass the following functions: (I) initial high activity of drug 
in the patch creates a severe gradient forcing the drug from the patch into the 
epidermis; (2) release of enhancer(s) to alter the diffusion coefficient of the drug in 
the stratum corneum; (3) release of cosolvent at a prescribed rate so as to modify 
nifedipine solubility in the lower epidermal and dermal layers. 
Conclusions - Unsaturated, long-chain acids had pronounced effects which appear to 
be selective for cis-unsaturated fatty acids as they were not observed for their 
saturated ( myristic, and nonadecanoic) or trans-unsaturated acids (elaidic) 
counterparts. It was found that the permeability of nifedipine through hairless mouse 
skin is controlled by both the solubility of the drug in the donor and the ability of 
donor to both disturb and pass through the epidermal skin layers. The shape of Q vs 
t plots displayed a strong dependency on the quantity of cosolvent applied . These 
results imply that a linkage between nifedipine and vehicle codiffusion may exist and 
further studies to establish the nature of this dependency are presently underway. 
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FORMULATION OPTIMIZATION 
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ABSTRACT 
The effects of transdermal device components on nifedipine permeation were 
evaluated by (l) identifying those factors which significantly affect the permeation of 
nifedipine and (2) selecting levels for these factors which optimize flux and lag times. 
Of primary interest was the role of solubility and its influence on the permeation 
enhancers chosen to increase the skin permeability of this hydrophobic calcium 
channel blocker. A McLean Anderson mixture design was employed to obtain a 
stoichiometric interpretation of the permeation process. In addition to demonstrating 
solvent-induced permeation enhancement, the mechanisms by which solvents enhance 
permeation are discussed. The ultimate objective was to apply regression techniques 
to interpret, on a molar basis, the data obtained from in vitro permeation experiments. 
The model obtained was used to identify both the magnitude and significance of the 
synergism between formulation components and to optimize the desired response. 
Data from these inquiries have contributed toward the rational selection of 
components in a viable transdermal dosage form that permit transdermal delivery of 
nifedipine at rates in excess of the 31 µg/h•cm2 required for potential therapeutic 
response. 
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Introduction 
Propylene glycol (PG) , ethanol (ET) and dimethylisosorbide (DM) are known 
to be well absorbed when administered topically . The results of previous experiments 
infer that the skin permeability of nifedipine is related to the volume of donor 
cosolvent applied, suggesting that a reservoir-type device would be best suited to 
deliver drug and enhancer to the skin . The results obtained from differential scanning 
calorimetry show nifedipine to have strong intermolecular attractions, leading to the 
hypothesis that solubilization of drug may provide a means of increasing the amount 
of nifedipine molecules available for diffusion . Information obtained from previous 
solubil ity studies indicate that movement of nifedipine from the epidermis to an 
environment of extensive hydrogen bonding characteristic of the hydrated dermis is 
likely to lower the driving force of diffusion . Thus, formulation components were 
purposely selected for their potential to solubilize and facilitate nifedipine diffusion 
across the epidermis and dermis. 
Visualization of the permeation process as an intimate relationship between a 
finite ratio of formulation components may offer clues into the mechanism of the 
transdermal diffusion process. Inherent in the stoichiometric approach is that a 
change in one component requires collateral change in the next; a deficiency best 
handled by the mixture experimental designs. It is difficult to interpret the results of 
experiments involving mixtures of more than three components. This partly due to 
the inability to visualize spatially the effect of a change in a dependent variable on the 
measured response. In addition , any change in proportion of one component must be 
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coupled to changes elsewhere in the composition of the mixture, rendering a 
superficial interpretation of the response quite meaningless. These two qualities pose 
an intractable problem best solved by several published mixture experimental 
designs. 1 A distinguishing feature of these designs is that the independent, 
controllable factors represent non-negative, proportionate amounts of the mixture 
components rather than unrestrained amounts which must of course sum to unity . 
The problems associated with identifying a blend of formulation components 
which would allow adequate permeability with minimal irritancy and lag time at a 
reasonable cost, may be solved using mixture response surface methodology. 
Typically the effects of various factors on certain characteristics of a system are 
studied, with an eye toward: (!) identifying those factors which significantly affect 
permeation, and (2) selecting levels for these factors which optimize the permeation 
characteristics. The first step involves the statistical problem of fitting a model to 
experimental data to disclose which factor level combinations are critical or not 
necessary to control. The second step, for the model disclosed in the first step, 
involves finding the combination of the factor levels that either minimize or maximize 
the response. Although the factors are observed only at a finite number of values, the 
factors are treated as continuous variables. Using the ranges of each factor, we 
interpolate over their composite range in order to optimize the responses. We employ 
various facilities available in the SAS system in conjunction with a modified McLean 
and Anderson experimental design with the objective of optimizing levels of 
formulation components which maximize flux yet minimize lag time. 
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METHODS 
Kinetic studies - The in vitro release of nifedipine was investigated by applying 
cosolvent mixtures containing 10% excess suspended nifedipine to freshly excised 
hairless mouse skin mounted in vertical Franz cells. Equimolar amounts (IO µmol of 
cosolvent) of the various donor formulations are applied to all cells and the 
experiment conducted as described previously.2 We adopt the convention of 
expressing the levels of the factors (i.e., the relative amounts of formulation 
components) in terms of mole fraction. The responses of interest are the lag time and 
steady state flux and represent the average values taken over 4 replicates of each 
formulation. Samples of the receptor phases (3ml) were removed, filtered through 
0.45 micron filters and 1 ml reserved for HPLC analysis. Serial sampling was 
generally performed at 2,4,6,8,10,12,15,18,21 and 24 hours after the suspensions 
were applied. The samples of receptor fluid were placed in amber vials, labelled and 
immediately analyzed. A stability-indicating HPLC method was employed to measure 
skin permeation kinetics. 
Data analysis - The experimental design, designated Design I, constitutes a 
polyhedron whose centroids are established by a two-step procedure described by 
McLean and Anderson. 3 Mixtures of propylene glycol (x,), oleic acid (x,), ethanol 
(x3) and dimethylisosorbide (x,) were prepared in a manner such that their proportions 
are non-negative, must sum to unity and are restricted to the following upper and 
lower bounds: 
10% < x, < 72% 
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8% < X2 < 25 % 
10% < x, < 25 % 
10% < X4 < 70% 
The design points comprise the vertices and centroids of a convex polyhedron suitable 
for fitting first-degree and quadratic models in the constrained mixture space. The 
resulting factor space and the design point designations are presented in Figure 16. 
Insight gained from this design permitted tighter constraints on the experimental space 
such that the mole fraction of OA and ET was fixed at the 10% level and the levels of 
the other two components were allowed to vary. This second experiment is referred 
to as Design II. Experimental design, analysis and optimization were performed 
using the ADX™ menu system of SAS/QC and SAS/STAT software, Version 6.0 
(SAS Institute, Inc. Carey, NC). 
Results and Discussion 
Of the many factors that will influence the effectiveness of penetration 
enhancers, this study focuses on the physicochemical properties of the permeant and 
vehicle with the objective of relating, on a molecular level, how the four components 
affect both responses of flux and lag time. It is unlikely that for this multi-response 
problem there exists a unique combination of factors which result in optimum values 
for both responses simultaneously. Instead, we first identify the different sets of 
factors affecting the different responses. Once these two sets are defined, a 
compromise is accepted by optimizing flux while holding the lag time under a certain 
level. The data in Table X represent permeation measurements obtained from Design 
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( I. While the maximum flux in Table X is attained at high values of oleic acid, 
reasonable flux values are also observed for low values of this factor. Acceptable 
flux and lag times were obtained from systems containing levels of oleic acid far 
below its upper constraint of 25 % . Likewise, Table XI shows that better fluxes are 
obtained with lower (10-20%) levels of DM. Also, since OA is the more chemically 
labile, irritating to the skin and expensive than any of the other factors, it is important 
to limit the amount of this critical component in the proposed transdermal delivery 
system. 
The results which appear in Table X and Table XI offer the following 
observations: (1) quaternary mixtures using OA and ET both at the 10% level offer 
significant enhancement of flux values; (2) lag times were clearly longer for 
formulations containing levels of DM exceeding 20-30%; (3) both lag time and flux 
are improved by limiting the level of DM to less than 20% . These results suggest 
that a relatively high level of PG and low levels of OA, ET and DM will give 
maximum flux and minimum lag times. A possible interpretation of these 
observations is as follows. Although the disposition of DM following topical 
administration is unresolved, it is a universal solvent believed to readily pass the 
epidermis.• Curiously, the single solvent solubility of nifedipine is highest in DM 
(85mg/ml) than in OA (0.m/ml) , ethanol (17mg/ml) or PG (14mg/ml). Previous 
solubility studies revealed that nifedipine solubility in binary mixtures of PG and DM 
drop precipitously as small amounts of water are added to form ternary PG:DM:water 
mixtures. Given its very low aqueous solubility ( - 0.006 mg/ml) nifedipine would 
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Propylene glycol 
~x, 
Oleic acid 
DMI 
Ethanol 
Figure 16. Experimental sample space for the four component McLean Anderson 
mixture design (X, =PG; X2 = 0A; X3 =ET; X4 =DM) . 
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Table X. Design I. Quaternary systems data for a four-component simplex-centroid 
design: PG, OA, ET, and DM for donor suspensions using the following constraints: 
PG=l0-75, OA=l0-36, ET=l0-36, DM=l0-75. 
Mole Fraction Percent Response Variables 
N PG OA ET DM Lag time J 
(hours) (ug/h•cm2) 
1 72 10 8 10 2.4 ± 1.0 148.9 ± 60.6 
2 55 25 10 10 2.0 ± 2.2 60.0 ± 25.3 
3 55 10 25 10 1.9 ± 5.7 96.0 ± 53.1 
4 10 10 25 55 3.3 ± 0.8 12.2 ± 2.4 
5 10 10 10 70 4.8 ± 0.3 11.0 ± 0.8 
6 25 10 10 55 3.7 ± 0.4 58.8 ± 45.7 
7 14 36 36 14 3.8 ± 0.6 48.2 ± 7.5 
8 10 25 25 40 7.6 ± 1.0 48.2 ± 5.5 
9 25 25 25 25 2.5 ± 1.4 120.2 ± 10.3 
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Table XI. Design Il. Four-component simplex-centroid blending propylene glycol 
(PG), cis-oleic acid (OA), ethanol (E1), and dimethylisosorbide (DM) for donor 
suspensions keeping [OA] and [ET] ~ 10% . 
Mole Fraction Percent Lag 
Time J 
N PG OA ET DM (hours) (ug/h•cm2) 
1 97 l 1 1 3.8 ± 0.6 110 ± 16 
2 88 1 1 JO 7.6 ± 1.0 106 ± 25 
3 88 JO 1 1 2.0 ± 0.5 60 ± 30 
4 79 10 l 10 2.3 ± 0.3 117 ± 10 
5 88 1 JO 1 5. 1 ± 0.7 80 ± 19 
6 79 1 JO JO 4.8 ± 0.4 103 ± 10 
7 79 JO JO 1 0.7 ± 0.4 IOI± 2 
8 70 JO JO 10 2.4 ± 1.0 149 ± 6 
9 82 6 6 6 3.3 ± 1.3 104 ± 46 
JO 88 6 6 1 3 131 
11 79 6 6 10 2 111 
12 88 6 1 6 3 109 
13 79 6 JO 6 2 125 
14 88 1 6 6 3 99 
15 79 10 6 6 2 127 
KEY: Design points, N, 1-8 represent vertices; point 9 represents the overall 
centroid; points I0-15 represent face centroids. J is the steady state flux in 
ug/h•cm2 reported as the mean ± s.d. of 4 cells except points 10-15 which were 
single determinations .. 
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have little affinity for the hydrated epidermis and consequently the diffusional driving 
force from the donor into the dermal layers is likely to be lower. A possible 
explanation why poorer fluxes and shorter lag times were obtained from those 
formulations containing only small quantities of DM is that although DM is a good 
solvent and effectively increases the amount of nifedipine readily available in 
solution, donors with high fractions of DM may impede nifedipine permeation by 
altering nifedipine partitioning in favor of the donor phase. This effect would be 
expected to dissipate with time as DM levels fall in the donor. If this were true, 
donors with greater mole fraction DM would display longer lag times. 
To test this theory, Design 11 was augmented with additional formulations 
such that the ratio of OA to ET was held constant and the proportion of PG to DM 
allowed to vary. These results, reported in Table XII, show a monotonic decrease in 
lag time as the level of DM falls. For this series of experiments a clear demarkation 
was observed in the character of the Q versus t profiles as the ratio of PG to DM 
varied. A portion of the data, represented in Figure 17, shows the disparate nature of 
the curves. Donor formulations with DM levels exceeding 20% consistently 
displayed lag times of 10 hours or more which were significantly different from the 
lag times observed in donors with less than 10% DM. Formulations containing less 
than 30-40% DM display asymptotic behavior with the Q versus t curve leveling out 
at around 18 hours; this behavior was not observed for formulations whose DM 
content exceeded 50%. Interestingly, formulations containing 30 to 60% DM did not 
demonstrate this asymptotic leveling but exhibited biphasic Q versus T profiles, 
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making the determination of lag time extremely subjective. For the biphasic profiles, 
since the latter portion of the profile might possibly represent chemical damage to the 
skin induced by donor formulation, the lag time and flux values were obtained from 
the initial portion of the curves. Asymptotic and biphasic Q versus T profiles were 
not observed in formulations in which the level of DM exceeds 70 %. The permeation 
rates displayed by these formulations were so low that they are indistinguishable from 
the abscissa in Figure I 7. 
Table XJI. Quaternary systems data for a four-component blending propylene glycol 
(PG), cis-oleic acid (OA) , ethanol (ET) , and dimethylisosorbide (DM) donor 
suspensions keeping OA:ET ratio constrained at IO: IO. 
Mole Fraction Percent Lag 
N Time J 
PG OA ET DM (hours) (ug/h•cm2) 
I I IO 10 79 4.0 ± 0.7 10.7 ± 4 
2 IO IO IO 70 4.2 ± 0.8 Il.O ± I 
3 20 IO IO 60 I2.3 ± 2.2 3.5 ± 2 
4 30 IO IO 50 10.0 ± 1.7 4.2 ±I 
5 40 IO IO 40 12.0 ± 2.6 16.0 ± 6 
6 50 10 IO 30 JO.I± 4.3 127.8 ± 134 
7 60 IO IO 20 5.1 ± 0.6 216.2 ± 44 
8 70 IO IO IO 2.4 ± 1.0 148.9 ± 6I 
9 79 10 IO I 0.7 ± 0.4 IOl.O ± I2 
KEY: N = formul ation designation; J = flux in µg/h•cm2. 
Formulations containing less than 30-40% DM displayed Q versus T curves 
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Figure 17. Effect of high and low levels of dimethylisosorbide in quaternary mixtures 
holding ratio of OA:ET at 10: 10, n =4. 
that leveled out at around 18 hours . While each factor-level combination receives 
the same number of solvent molecules, all donor formulations consist of suspensions 
of 10% excess nifedipine so that the amount of nifedipine actually applied to the skin 
does vary as a function of nifedipine solubility in the formulation . Only rarely did 
the total amount of nifedipine permeated approach the amount initially applied and 
these formulation were biphasic rather than asymptotic . Since this asymptotic 
behavior is restricted to donor formulations at low levels of DM, it was initially 
believed to result from depletion of DM in the donor. To test this theory, a 
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formulation consisting of PG:OA:ET:DM (50: 10: 10:30) were applied in doses of 6 
and 18 µmo! of cosolvent per cell. In Figure 18, Q versus T profiles of the lower 
dose asymptotes; cells receiving the higher dose did not display an asymptote. Upon 
termination of the experiment, the amount of nifedipine remaining in the donor 
compartment of those cells showing asymptotes revealed that for the 6 µmol dose, the 
amount of nifedipine permeated is approximately 16% of the amount initially applied. 
The amount of nifedipine recovered in the skin was comparatively small ( ,.,33 of 
amount permeated). Crystals of nifedipine were visible in all donor compartments 
and it is assumed that a sufficient excess of drug ( ""80%) remained to maintain the 
concentration gradient. In terms of nifedipine solubility, donors high in PG and low 
in DM possess a lower saturation solubility. Also, as DM diffuses into the skin, the 
donor simultaneously acquires transpired moisture from the skin, the net effect of 
which is to lower nifedipine solubility and create a diffusional force favoring partition 
of nifedipine out of the donor and into the skin. Furthermore, it has been proposed 
that solvents alter the dermal environment by alteration of hydrogen bonding of 
dermal water or by its ability to solubilize drug. This combination of events alters 
drug solubility during the experimental period in a manner that favors nifedipine 
permeation and is consistent with the observation of asymptotic or biphasic behavior. 
The expression of formulation constituents as mole fraction permits a unique 
opportunity to model the diffusion process from a stoichiometric perspective. 
Adoption of this reference system permits the experimental data to be modeled in a 
meaningful way that illuminates the relative importance of the individual components 
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Figure 18. Effect of trebling amount of cosolvent applied from 6 to 18 micromoles. 
and, more importantly, better demonstrate the potential interaction between 
components. Regression techniques applied to the data in Table Xl resulted in a 
model predictive of flux and lag time. The criterion for best fit were consideration of 
the correlation coefficient, residual pattern, sum of squared residuals among the 
various models tested . The parameter estimates are shown in Table XIII and the 
significance of the regression is shown in Table XlV . The magnitude of the 
parameter estimates in Table XIII reveal that all four main effects were not 
significant. Of the six possible two-way interactions, the synergistic blending of OA 
appears to be real since all fJ;; for i =j =2 terms are greater than zero. Synergism 
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among the other components may not be real, since (3• is not significantly greater than 
zero based on the comparison of each coefficient estimate to the value of its standard 
error in the form of an approximate Student's t-statistic and then comparing each 
computed value of t to the tabled value t, 5,0.25 • The high standard error terms. due in 
large measure to biological variability of the skin, did not detract from the fitting of 
the polynomial and the error due to regression (r=0.83) is acceptable. The sign of 
the (3's and the corresponding value of the I-statistic lead us to infer that most 
individual terms are antagonistic toward one another in overall formulation 
performance while combinations of X2 (i.e., oleic acid) strongly interacts with the 
other three factors. This result was anticipated, since the components had poor 
permeation profiles when applied individually. Furthermore, the magnitude of the 
interaction terms are large relative to the single factor terms and probably represents 
the driving force for enhanced permeability in these systems. 
The elucidation of the synergistic interactions among vehicle components 
responsible for the superior performance of these quaternary systems is a conclusion 
difficult to identify in four factor space and emphasizes the importance of treating the 
data to this type of analysis. Gross observation of the Q versus t profiles would have 
led to the (incorrect) conclusion that DMI had a deleterious effect on permeation. 
However, the model predicts that it is not so much the main effects, but rather the 
interaction between OA and the other three components which explains enhanced 
permeation. 
Since all four factors affect the response, it is not possible to identify a region 
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Table XIII. Parameter estimates from data presented in Table XI. 
Parameter Estimates 
OF Parameter Standard 
Variable' Estimate Error t2 
x, l 100.5 27.1 3.715 
X2 I -3369.0 1588.l -2.121 
x, I -1773.4 1605.6 -1.105 
x. l -146.3 111.l -1.317 
X,*X2 I 3990.3 1912.4 2.087 
X1*X3 l 2098.5 1898.5 1.105 
x,•x. I -14.7 167.3 -0.088 
X2*X, l 9573.7 4502.8 2. 126 
X2*X4 I 4658.8 2257.0 2.064 
x,•x. I 1945.4 2356.0 0.826 
1X1 = propylene glycol; X2 = oleic acid; X3 = ethanol; X4 = 
dimethylisosorbide. 
p > ITI 
0.0016 
0.0480 
0.2839 
0.2044 
0.0514 
0.2836 
0.9308 
0.0476 
0.0537 
0.4198 
2t = computed value of Student' s I-statistic (tabled value t1s.o.25 = 0.691). 
of maximum (or minimum) response in three-dimensional terms because they are 
hyperplanes in four-dimensional space. Futhermore, the canonical analysis of the 
fitted surface yield negative and positive eigenvalues, indicative of a saddle region of 
"good" formulations rather than a unique optimum point for both flux and lag time. 
Therefore, although a predictive model has been developed, it is unlikely that for this 
multi-response problem there exists a unique combination of factors which result in 
optimum values for both responses simultaneously. 
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Table XIV. Analysis of Variance of data presented in Table XI. 
Analysis of Variance 
Sum of Mean F Value Prob>F 
Source DF Squares Square 
Model 10 212635.7 212653.6 14.4 0 .0001 
Error 18 26579.1 1476.6 
Total 28 239214.8 
Root MSE = 38.4 
Dep Mean = 75.3 R-square = 0.8889 
c.v. = 51.0 Adj R-sq = 0.8272 
The predicted response surface for flux (Figure 19) and lag time (Figure 20) 
correspond exclusively to systems in which the level of both oleic acid and ethanol is 
held at the mole fraction level of 10%. Unfortunately, since all four two-way 
interactions with OA and the remaining factors affect the response, such plots cannot 
be readily used to identify a region of maximum (or minimum) response for the 
present n +4 factor space. One solution is to set constraints on lag time and optimize 
flux subject to this constraint. As an alternative, a ridge analysis is used to locate the 
range of 'optimum' response within the design space. As a second alternative, the 
predicted response surface for flux within the constraints of three factors may be 
examined at discrete levels of the fourth factor in a manner analogous to a 
radiological CAT scan. Such conceptualizations, produced under the SAS ADX 
system, offer an advantage over the three-dimensional plot in Figure 19 in that they 
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Table XV. Ridge analysis of data in Table XI. 
----- Type of ridge = MINIMUM -----
x, X2 x, x. PRED STERR 
0.49 0.11 0. 11 0.29 89.07 16.82 
0.45 0.10 0.10 0.34 77.73 17.44 
0.41 0.10 0.10 0.39 66.10 17.99 
0.37 0.09 0.10 0.44 54.09 18.66 
0.35 0.08 0.09 0.48 41.58 19.78 
0.32 0.07 0.09 0.52 28.45 21.86 
0.29 0.06 0.09 0.56 14.56 25 .31 
0.26 0.05 0.09 0.60 0.20 30.31 
0.24 0.04 0.10 0.63 0.0 36.83 
0.22 0.03 0.10 0.66 0.0 44.69 
0.20 0.01 0.10 0.69 0.0 53.70 
----- Type of ridge = MAXIMUM -----
0.49 0. 11 0. 11 0.29 89 .07 16.82 
0.53 0.13 0.11 0.24 100.20 16.22 
0.58 0. 12 0. 12 0.19 111.17 15.81 
0.62 0.12 0.12 0.14 122.05 16.16 
0.66 0.12 0.12 0.09 132.88 17.80 
0.71 0. 12 0.13 0.04 143.56 21.03 
X1 = propylene glycol; X2 = oleic acid; X3 = ethanol; X4 = dimethylisosorbide. 
permit visualization of three rather than two factors (Figure 21 through Figure 24). 
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Figure 19. Three dimensional response surface and contour map of the predicted flux 
in quaternary mixtures studied (oleic acid and ethanol both at the 10% level) . 
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Figure 20. Three dimensional response surface and contour map of the predicted lag 
time in the quaternary mixtures studied (oleic acid and ethanol both at the 10% level). 
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Figure 25. Contours of the standard error of predicted flux responses for formulations 
in Figure 23. 
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Figure 26. Permeation of nifedipine from formulations of high propylene glycol 
content. 
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The eigenvalues and eigenvectors obtained from regression analysis predict 
elliptical response surfaces for both lag time and flux that are most sensitive to 
changes in the levels of OA and DM, while the level of PG relative to these key 
components should not influence the slope of either response surface as significantly. 
This behavior is readily apparent in Figure 21 through Figure 24 which are serial 
slices taken along the DMI (i.e., X..) axis of the theoretical sample space represented 
by the polyhedron in Figure 16. Data treated in this manner permits visualization of 
the contour map of fluxes predicted from mixtures of PG, OA and ET at discrete 
levels of DMI. Determination of the composition of any formulation within the 
confines of the triangular space conforms with the rules governing standard ternary 
phase diagrams. The contour intervals running parallel to the PG axis (vertically) 
indicate that the flux response is least sensitive to this component. Regions having 
narrow contour intervals, such as those parallel to the base of Figure 21, predict that 
the flux response will change rapidly with changes corresponding to horizontal 
movement from regions of low to high oleic acid. Clearly, movement in this 
direction results in rapid achievement of optimal fluxes followed by equally rapid 
decline in predicted permeation rates. An additional feature of the system is that it 
also provides a measure of confidence in the response estimates via plotting of the 
standard error as shown in Figure 25. These results suggest that a relatively high 
level of PG and low levels of OA, ET and DM will give maximum flux and minimum 
Jag times. 
From a stoichiometric perspective, the diffusion process to be envisioned as 
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one in which OA and DM are the rate limjting factors, while ET and PG have less 
activity and are present in excess. Based on these results of the regression, optimal 
performance should be realized from a formulation high in PG relative to the other 
components. A compromise is accepted in formulation 9 in Table XII (i.e., 
PG:OA:ET:DM = 79: 10: 10: 1) which optimize flux to 100.99 ± 2 µg/h•cm2 while 
holding the lag time under six hours. The effect of OA, ET and DM concentrations 
relative to each other while holding the level of PG at 79 % are shown in Figure 26. 
The results of these permeation experiments conform to predictions based on 
eigenvalues obtained from the model obtained from the data in Table X 
The minimum and maximum predicted flux response values expected from 
various formulation combinations are shown in Table XV. The maximum flux 
predicted by the model was expected from a mole fraction ratio of 70: 12: 13:5, the 
permeation results which are presented in Figure 15. Note that this ridge maximum 
is outside the constraints of the polyhedron withjn Figure 16. and the amount of error 
Hkely to be incurred generally rises on the periphery of the experimental space. 
Figure 25 shows that all approximation are expected to be particularly imprecise near 
the edges of the experimental region determined by the design space. This optimized 
formulation (designated P42. l) yielded a flux of 60 ± 6 µg/h•cm2 and a lag time of 
only 2 hours which is twice that required to deliver an equivalent oral druly dose. 
In summary, regression analysis have been successfully applied to data 
obtained from permeation experiments to identify positive synergistic interactions 
among formulation components. The intractable nature of mixture designs was 
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overcome by using a McLean Anderson experimental design which permitted the 
results of the permeation studies to be interpreted in a stoichiometric fashion. 
Mathematical techniques successfully modeled the permeation process so that 
quantitative predictions of the flux or lag time could be made in n + 3 dimensional 
space. These observations support conclusions reached earlier regarding the 
importance of solubility of the permeant in the donor phase, the codiffusion of solvent 
with drug, and the general conditions necessary to promote the percutaneous 
absorption of compounds with poor solubility profiles. This novel approach 
facilitated the rational selection of components in transdermal dosage forms that 
permitted systemic drug availability of a magnitude required for potential therapeutic 
response. 
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APPENDIX A: 
COMPUTER PROGRAM SOURCE CODE 
DESCRIPTION AND LISTINGS 
INTRODUCTION 
This appendix describes the computer programs written for this study. Since 
screening studies typically generate large quantities of data, standard operating 
procedures for data coding, storage and processing that are both rugged and robust 
are of inestimable value in all areas of research. In addition, optimization problems, 
which are numerically intensive, have evolved and now permeate many areas of 
research. For these reasons, an IBM mainframe was employed, for it offered 
virtually unlimited access to storage and data processing capabilities. The language 
chosen for this work was the SAS language running under the FSVM environment on 
the Academic Computer Center IBM mainframe. 
This section provides an overview of the general purpose of the two programs 
entitled CELLS3 SAS Al and SIMPLEX SAS Al. Briefly, the function of CELLS3 
SAS Al is calculate flux and lag times by determining the amount of nifedipine 
permeated versus time. The source code is provided because it utilizes an algorithm 
for handling large, complex data sets that can be applied to many fields of research. 
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The source code for SIMPLEX SAS Al is also supplied as it shows the means by 
which the various properties of the formulation studied were calculated. 
In our laboratory, a Waters Baseline 810 chromatography workstation has been 
programmed to acquire data under its Summary option to allow storage of data on 
floppy disk to be uploaded to the mainframe via a modem telecommunications link. 
A novel method for coding the individual data points was developed. This scheme 
was successfully utilized by six researchers sharing the apparatus to manage thousands 
of data points without mishap. In addition, it provides a functionally useful format to 
be read by subsequent data processing steps in the SAS system . The specifics of this 
program are discussed in detail in the section titled "CELLS3 SAS Al" . 
CELLS3 SAS A I 
A particularly useful format for maintaining integrity of the data sets that also 
provides for efficient identification and retrieval has been to code the data points in 
the following hierarchal structure: assay, notebook page, formulation reference, 
replicate number (i.e., variables VI thorough V4) followed by the drive unit position, 
sample interval, and the time the sample was taken. This is accomplished by first 
allocating space in a hard disk subdirectory and then assigning each chromatogram a 
unique 8 digit filename and sample name in the "LOAD QUE" option. Following 
data acquisition and storage as an ASCII file on floppy disk , the sample names (which 
are comprised of the four identifiers VI thorough V4 assigned in the "LOAD QUE" 
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step) are quickly expanded, using the "SEARCH/REPLACE" feature of any 
wordprocessor, to the format utilized by the INPUT statement in the data step DATA 
ASCON in program CELLS3 SAS AL CELLS3 SAS Al was written in modular 
fashion using the SAS macro facilities which allow for a great deal of versatility. 
Results from the analysis can be stored in a sequential text file with the 
following format: (1) method (2) notebook (3) formulation, (4) replicate, (5) etc. 
"Method" refers to the Baseline 810 program containing the instructions used to 
inject, acquire, and process chromatograms and calculate the amount of nifedipine 
using peak areas by the external standard method. 
It is essential that the user of the SAS ADX'M menu (SAS Institute Inc. Carey, 
NC) be aware that the device driver of the present version of SAS (6.01) at this 
installation must be modified in order to obtain hardcopy of graphics produced. Prior 
to invoking the SAS ADX system at URI, the user must insure that the following 
essential steps have been properly executed: 
(1) the Q2200PS driver has been modified from REPLACE to APPEND. 
(2) the following statements : 
X FILE GSASFrLE DISK filename filetype filemode; 
GOPTIONS SWAP GACCESS=GSASFILE DEVICE=Q2200PS; RUN; 
are submitted by the user from the Display Manager Screen prior to invoking the SAS 
ADX system. The first statement instructs the mainframe where to hold the graphics, 
while the second statement configures the SAS system to URI standards. The SAS 
ADX system is invoked from the Display Manager by typing DESIGN on the 
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program line. At this point, the user may engage in an interactive session with the 
SAS ADX menu system that conforms to those instructions found in the manual.' 
ADX is configured to display color graphics upon any graphics terminal by 
specifying "DEVICE=TEK4107" when prompted by the system. Direction of 
graphics output from the SAS ADX system to the University laser printer requires 
that the user exit the ADX system and at the CMS READY prompt type FILEL, tab 
down to the 'filename filetype filemode' (i.e. , the repository of the graphic stream 
provided to the system in the statement above) and typing the following command 
RPRINT I LP 1 PS 
upon which the graphic image may be recovered at the Dispatch Office in Tyler Hall. 
1 Brown, Jason J. and Randall D. Tobias, ADX Menu System Examples: 
Preliminary Version February 1991. Statistical Quality Improvement R & D 
Applications Division, SAS Institute Inc. SAS Campus Drive Carey, NC 27513. 
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********************************************************************** 
* PROGRAM: CELLS3 SAS Al 
* FUNCTION: SUBDIVIDE TOTAL DAT INTO SUBSETS, 
PERFORM GRAPHICS & STATISTICS. 
* AUTHOR: EMILIO SQUILLANTE 
* VALIDATED: 10/16/92 
**********************************************************************; 
/*begin vardic********************************************* 
LOWT 
HIGHT 
Vl 
V2 
V3 
V4 
TIME 
INT 
POSI 
DICTIONARY OF VARIABLES: 
MINIMUM TIME VALUE IN FLUX DETERMINATION 
MAXIMUM TIME VALUE IN FLUX DETERMINATION 
BASELINE ASSAY METHOD. 
NOTEBOOK PAGE FOR SPECIFICS OF EXPERIMENT CONDITIONS. 
FORMULATION (DONOR COMPOSITION,, ETC . ) 
REPLICATE OF VARIABLE 'V3'. 
TIME THAT SAMPLE WAS TAKEN. 
SEQUENCE THAT SAMPLE WAS TAKEN. 
POSITION OF FRANTZ CELL IN MAGNETIC STIRRER. 
************************************************end vardic*/ 
%LET PROGRAM = CELLS3.SAS.Al; 
%LET SOURCE = P25 DAT Al; 
CMS FILEDEF INF2 DISK &SOURCE; 
* DAT Al: P45 P42 P32 P25 Pll P6 86 UP79_82; 
* RESP Al: UPL RESPONSE SMALLDAT ; 
* CMS FILEDEF OUTFILEl DISK SASDS DAT Al; 
* CMS FILEDEF OUTFILE2 DISK T2 DAT Al; 
* OPTIONS MPRINT MACROGEN SYMBOLGEN; 
OPTIONS NOSOURCE NONOTES; 
%GLOBAL LOWT HIGHT JM PROGRAM SOURCE 
Cll Cl2 Cl3 Cl4 ClS Cl6 Cl7 ClB Cl9 
C21 C22 C23 C24 C25 C26 C27 C28 C29 
C31 C32 C33 C34 C35 C36 C37 C38 C39 
C41 C42 C43 C44 C45 C46 C47 C48 C49 
CSl C52 C53 C54 CSS C56 C57 CSB C59 
C61 C62 C63 C64 C65 C66 C67 C68 C69 
Vll Vl2 Vl3 Vl4 VlS Vl6 Vl7 VlB V21 
V21 V22 V23 V24 V25 V26 V27 V28 V29 
V31 V32 V33 V34 V35 V36 V37 V38 V39 
V41 V42 V43 V44 V45 V46 V47 V48 V49 
VSl VS2 VS3 VS4 VSS VS6 VS7 VSB VS9 
V61 V62 V63 V64 V65 V66 V67 V68 V69 
Xll Xl2 Xl3 Xl4 XlS Xl6 Xl7 XlB Xl9 
X21 X22 X23 X24 X25 X26 X27 X28 X29 
X31 X32 X33 X34 X35 X36 X37 X38 X39 
X41 X42 X43 X44 X45 X46 X47 X48 X49 
XSl XS2 XS3 XS4 XSS XS6 X57 XSB XS9 
X61 X62 X63 X64 X65 X66 X67 X68 X69 
CllO Clll Cll2 Cll3 Cll4 CllS Cll6 Cll7 CllB 
C210 C2ll C212 C213 C214 C215 C216 C217 C218 
C310 C311 C312 C313 C314 C315 C316 C317 C318 
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... 
C410 C411 C412 C413 C414 C41S C416 C417 C418 
CSlO CSll CS12 CS13 CS14 CSlS CS16 CS17 CS18 
C610 C611 C612 C613 C614 C61S C616 C617 C618 
VllO Vlll Vll2 Vll3 Vll4 VllS Vll6 Vll7 V210 
V210 V211 V212 V213 V214 V21S V216 V217 V218 
V310 V311 V312 V313 V314 V31S V316 V317 V318 
V410 V411 V412 V413 V414 V41S V416 V417 V418 
VS10 VSll VS12 VS13 VS14 VSlS VS16 VS17 VS18 
V610 V611 V612 V613 V614 V61S V616 V617 V618 
XllO Xlll Xll2 Xll3 Xll4 XllS Xll6 Xll7 XllB 
X210 X211 X212 X213 X214 X21S X216 X217 X218 
X310 X311 X312 X313 X314 X31S X316 X317 X318 
X410 X411 X412 X413 X414 X41S X416 X417 X418 
XSlO XSll XS12 XS13 XS14 XSlS XS16 XS17 XS18 
X610 X611 X612 X613 X614 X61S X616 X617 X618 
%LET LOWT = 3; %LET HIGHT = 16; 
TITLEl "PROGRAM = &&PROGRAM CALLING DATA SET= &&SOURCE"; 
DATA COMPOS; 
MISSING Q; 
INPUT V3 $ Cl$ C2 $ C3 C4 $ CS$ C6 Xl X2 X3 X4 XS X6; 
Cards ; 
N41 . l PG OA ET DM Q Q 0 21 0 79 0 0 
N46.9 PG OA ET DM Q Q 0 7 0 93 0 0 
N63 PG OA ET DM Q Q 0 18 18 63 0 0 
N78.8 PG OA ET DM Q Q 21 8 7 61 0 0 
NBS.l PG OA ET DM Q Q 18 lS 67 0 0 0 
NBB.l PG OA ET DM Q Q 63 18 18 0 0 0 
NBB.2 PG OA ET DM Q Q 72 7 21 0 0 0 
Nl2 PG OA ET DM Q Q 0 2 0 98 0 0 
Pl4 PG OA ET DM Q Q 60 7 33 0 0 0 
N43.l PG OA ET DM Q Q 90 10 0 0 0 0 
M70 PGO PG OA ET DM Q Q 100 0 0 0 0 0 
M70- PG1 PG OA ET DM Q Q 20 0 0 80 0 0 
M70- PG2 PG OA ET DM Q Q 43 0 0 S7 0 0 
M70- PG3 PG OA ET DM Q Q 70 0 0 30 0 0 
M70-PG4 PG OA ET DM Q Q 87 0 0 13 0 0 
M70-PGS PG OA ET DM Q Q 95 0 0 s 0 0 
MBSA Q Q Q DM Q Q 0 0 0 100 0 0 
MBSB Q OA Q DM Q Q 0 s 0 9S 0 0 
PS.l PG IP OA AZ Q Q 2S 2S 2S 2S 0 0 
PS.2 IP OA AZ ET Q Q 2S 2S 25 2S 0 0 
PS.3 OA ET AZ DM Q Q 2S 2S 2S 2S 0 0 
PS.4 PG OA AZ ET Q Q 2S 2S 2S 2S 0 0 
PS.S IP AZ ET DM Q Q 2S 2S 2S 2S 0 0 
PS.6 PG OA ET DM Q Q 2S 2S 2S 2S 0 0 
P5.7 PG IP AZ DM Q Q 2S 2S 2S 2S 0 0 
PS.8 PG IP OA ET Q Q 2S 2S 2S 2S 0 0 
PS.9 IP OA AZ DM Q Q 2S 2S 2S 2S 0 0 
PS.10 PG AZ ET DM Q Q 2S 2S 25 2S 0 0 
PS.12 PG IP OA DM Q Q 2S 2S 25 2S 0 0 
PS. 13 PG OA ET DM Q Q 25 2S 2S 2S 0 0 
PS . 14 PG IP AZ ET Q Q 2S 2S 2S 2S 0 0 
PS.lS IP OA ET DM Q Q 2S 2S 25 2S 0 0 
PS.16 PG OA AZ DM Q Q 2S 2S 2S 2S 0 0 
PB.CA PG OA ET DM Q Q 0 100 0 0 0 0 
PlOAZ Q Q Q Q Q AZ 0 0 0 0 0 100 
PlOET Q Q ET Q Q Q 0 0 100 0 0 0 
P21. l PG OA ET DM Q Q 72 10 7 10 0 0 
P21.2 PG OA ET DM Q Q SS 2S 10 10 0 0 
P21.3 PG OA ET DM Q Q SS 10 2S 10 0 0 
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P21.4 PG OA ET DH Q Q 10 10 25 55 0 0 
P21.5 PG OA ET DH Q Q 10 10 10 70 0 0 
P21.6 PG OA ET DH Q Q 10 25 11 55 0 0 
P21. 7 PG OA ET DH Q Q 14 36 36 15 0 0 
P21.8 PG OA ET DH Q Q 10 25 25 40 0 0 
P25.4 PG OA ET DH Q Q 79 10 1 10 0 0 
P25.5 PG OA ET DH Q Q 79 1 10 10 0 0 
P25.6 PG OA ET DH Q Q 79 10 10 1 0 0 
P27.1 PG OA ET DH Q Q 97 1 1 1 0 0 
P27.2 PG OA ET DH Q Q 88 1 10 0 0 
P27.3 PG OA ET DH Q Q 88 10 1 0 0 
P27.5 PG OA ET DH Q Q 88 1 10 1 0 0 
P27.9 PG OA ET DH Q Q 83.5 5.5 5.5 5.5 0 0 
P28 . 3 PG OA ET DH Q Q 30 10 10 50 0 0 
P28.4 PG OA ET DH Q Q 40 10 10 40 0 0 
P28 . 5 PG OA ET DH Q Q 50 10 10 30 0 0 
P28.6 PG OA ET DH Q Q 60 10 10 20 0 0 
P28.9 PG OA ET DH Q Q 1 10 10 79 0 0 
P42.1 PG OA ET DH Q Q 71 12.2 12.9 4 0 0 
P42.2STR PG OA ET DH Q Q 71 12.2 12 .9 4 0 0 
\MACRO ASCON; 
*PURPOSE: MACRO ASCON IS INTENDED TO PROCESS BASELINE 810 DATA PROCESSED 
BY THE 'SUMMARY' FEATURE AND UPLOADED AS CONCENTRATIONENTER DATA SETS 
WITH Y-VAR=CONCENTRATION; 
DATA WOR!<. CONCl; 
MISSING Q; 
INFILE INF2; 
SLOPE=l; INTCPT=l; INT=l; DPVARl=l; RECVOL=l7; 
INPUT Vl $ V2 $ V3 $ V4 $ TIME INT POSI ADJCON; 
ARRAY V{*} Vl-V3; 
CUMAMT=RECVOL*ADJCON; 
LABEL V3='DONOR' V4='REPLICATE'; RUN; 
\MEND ASCON; 
\ASCON; 
* MERGE THE RESPONSE AND CONCENTRATION DATASETS; 
/* DATA CUMDAT; SET RESPONSl CONCl; * ! ! ! ! ! ! ! ! ! ! ; */ 
PROC SORT DATA=CONCl; BY V3; 
PROC SORT DATA=COMPOS; BY V3; 
DATA CUMDAT; MERGE CONCl COMPOS; BY V3; 
IF ADJCON = THEN DELETE; 
/*THESE STTS ALLOW EXPORT OF DATA TO EXTERNAL FILES; 
DATA NULL ; SET CUMDAT; FILE OUTFILE2; 
IF V3~'P27~1' OR V3='P27.2' THEN PUT V3 V4 TIME CUMAMT; 
•/ 
PROC SORT DATA=CUMDAT; BY V3 V4 TIME; RUN; 
PROC PRINT;VAR V2 V3 V4 TIME POSI ADJCON Cl C2 C3 C4 Xl X2 X3 X4; 
/* 
*BEGIN: CALCULATION OF INTERVAL DERIVATIVES (I.E., AMOUNT PERMEATED OVER 
EACH SAMPLING INTERVAL); 
PROC SORT DATA = CUMDAT OUT = SDERIV; BY V3 V4 TIME; 
DATA DERIV; SET SDERIV; DERIV=DIF(ADJCON); 
KEEP V2 V3 V4 POSI INT TIME ADJCON CUMAMT DERIV; 
TITLE3 'AMOUNT PERMEATED OVER EACH SAMPLING INTERVAL'; 
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TITLE4 'DERIVATIVES SORTED BY V3 V4 POSI AND TIME'; 
PROC PRINT NOOBS; RUN; 
*END: CALCULATE INTERVAL DERIVATIVES; 
*/ 
PROC SORT DATA=CUMDAT OUT=CUMDAT; BY V3 V4 TIME; 
DATA WORK.SEP; 
/* ---------------------------------------------------------
DATA SEP => FUNCTION IS TO PERFORM THE FOLLOWING: 
1. CREATE A VARIABLE 'EOFF' TO CONTAIN AN END OF FILE INDICATOR, 
2. RETAIN THE VALUE OF 'J' FROM PREVIOUS INTERATION OF DATA STEP, 
3. AND USE THE SYMPUT FUNCTION TO CREATE A MACROVARIABLE, 'JM', 
AND ASSIGN TO IT A VALUE FROM THE CURRENT DATA SET'S ITERATION 
(IE. 'J') NOTING THAT THE INITIAL VALUE OF J WAS O; 
-------------------------------------------------------- */ 
SET WORK.CUMDAT END=EOFF; 
BY V3-V4; 
RETAIN J;IF FIRST.VJ THEN J+l; 
IF EOFF THEN CALL SYMPUT('JM',J); 
IF EOFF THEN CALL SYMPUT('NUM ',J); 
IF EOFF THEN CALL SYMPUT('TOTAL', N ); 
RW; --
%MACRO CREATEl;/*SEPARATE 
%LOCAL H; 
INTO DISCRETE DATASETS BY FORMULATION*/ 
%LET H=l; 
%DO %WHILE (&H<=&JM); 
DATA WORK.EXDATA&H; 
SET WORK.SEP; 
IF J=&H; 
*; IF TIME > 
CALL SYMPUT( 'Xl' 
CALL SYMPUT ( 'X2 ' 
CALL SYMPUT( 'X3' 
CALL SYMPUT('X4' 
CALL SYMPUT('Cl' 
CALL SYMPUT( 'C2' 
CALL SYMPUT ( 'C3 ' 
CALL SYMPUT('C4' 
CALL SYMPUT('Vl' 
CALL SYMPUT('V2' 
CALL SYMPUT('V3' 
CALL SYMPUT('V4' 
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ILEFT(J),TRIM(Xl)); 
ILEFT(J),TRIM(X2)); 
ILEFT(J),TRIM(X3)); 
ILEFT(J),TRIM(X4)); 
ILEFT(J),TRIM(Cl)); 
ILEFT(J),TRIM(C2)); 
ILEFT(J),TRIM(C3)); 
ILEFT(J),TRIM(C4)); 
ILEFT(J),TRIM(Vl)); 
ILEFT(J),TRIM(V2)); 
ILEFT(J),TRIM(V3)); 
ILEFT(J),TRIM(V4)); 
PROC PRINT DATA=WORK.EXDATA&H NOOBS; 
TITLE2 
"OUTPUT: DATASET WORKEXDATA &H (MACROPRINT)" 
TITLE3 
"FORMULATION &&V3&H ASSAYED BY&&Vl&H (SEE NOTEBOOK PAGE=&&V2&H)"; 
TITLE4 
"DONOR: &&Cl&H=&&Xl&H &&C2&H=&&X2&H &&C3&H=&&X3&H &&C4&H=&&X4&H"; 
TITLES 
&&CS&H=&&XS&H &&C6&H=&&X6&H"; 
BY V3-V4 ; 
VAR Vl V2 V3 V4 INT TIME POSI DPVARl ADJCON CUMAMT; 
LABEL V2='NB PAGE:' V3='DONOR:' V4='REPLICATE:'; RUN; 
PROC SORT DATA=EXDATA&H OUT=WORK.EXDATA&H; BY V3 TIME DPVARl; 
PROC MEANS DATA=EXDATA&H 
MAXDEC=2 N MEAN STD STDERR MIN MAX CV 
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USS RANGE NMISS; 
BY V3 TIME; 
VAR DPVARl ADJCON CUMAMT; 
LABEL V2='NB PAGE' V3='DONOR ' V4='REPLICATE'; 
TITLE2 "OUTPUT: PROC MACROMEAN" 
TITLE3 
"MACRO MEAN: REQUESTED STATS BY NAME,TREATMENT AND TIME"; 
RUN; 
PROC PLOT DATA = EXDATA&H; PLOT CUMAMT * TIME = V4; RUN; 
TITLE2 "OUTPUT: DATASET WORKEXDATA &H (MACROPLOT)" ; 
TITLE3 
"FORMULATION &&V3&H ASSAYED BY&&Vl&H (SEE NBK PAGE=&&V2&H)"; 
TITLE4 
"DONOR:&&Cl&H=&&Xl&H &&C2&H=&&X2&H &&C3&H=&&X3&H &&C4&H=&&X4&H"; 
TITLES" &&CS&H=&&XS&H &&C6&H=&&X6&H"; 
DATA TRIMD&H; /* FUNCTION: EXCLUDES TIME POINTS FROM ANALYSIS */ 
SET EXDATA&H; 
*; IF TIME < &LOWT OR TIME > &HIGHT THEN DELETE; 
PROC SORT DATA=TRIMD&H OUT=WORK.TRIMD&H; 
BY V3 V4 POSI TIME ADJCON; RUN; 
PROC REG DATA=WORK.TRIMD&H; 
ID TIME; BY V3 V4; 
MODEL ADJCON=TIME I p R CL! CLM; 
OUTPUT OUT=C P=PRED L9S=L9S U9S=U9S R=RESID COOKD=COOKD; 
TITLE2 "OUTPUT: DATASET WORKEXDATA &H (MACROREG)" ; 
TITLE3"MACRO REG: REGRESSIONS FROM TIME= &&LOWT TO &&HIGHT"; 
TITLE4"FORMULATION &&V3&H ASSAYED BY&&Vl&H (SEE NOTEBOOK PAGE=&&V2&H)"; 
TITLES"DONOR =&&Cl&H=&&Xl&H &&C2&H=&&X2&H &&C3&H=&&X3&H &&C4&H=&&X4&H"; 
TITLE6" &&CS&H=&&XS&H &&C6&H=&&X6&H"; 
RUN; 
*/ 
/***********CONNECT QMS-1 LASER PRINTER 
*; OPTIONS DEVICE = TEK4107; 
DRIVER **********/ 
CMS CP SPOOL PRINTER PRTSRV; 
CMS CP TAG DEV PRINTER LPlPS; 
CMS FILEDEF GSASFILE PRINTER; 
GOPTIONS DEVICE=Q2200PS; 
/***********CONNECT QMS-1 LASER 
*; SYMBOLl C=BLACK V=STAR 
*; SYMBOL2 C=BLACK V=SQUARE 
*; SYMBOL3 C=BLACK V=TRIANGLE 
*; SYMBOL4 C=BLACK V=CIRCLE 
*; SYMBOLS C=BLACK V=DIAMOND 
*; SYMBOL6 C=BLACK V=HASH 
PRINTER DRIVER ***********/ 
W=2 H=2 L=l !=SPLINE; 
W=2 H=2 L=2 !=SPLINE; 
W=2 H=2 L=3 !=SPLINE; 
W=2 H=2 L=4 !=SPLINE; 
W=2 H=2 L=S !=SPLINE; 
W=2 H=2 L=l !=SPLINE; 
*; AXISl LABEL = (F=XSWISSB H=l.S 
VALUE (C=BLACK X F=SWISSB H=l) 
MINOR = NONE 
'TIME, HOURS') 
WIDTH = 1 
ORDER = 0 TO 24 BY 2; 
*; AXIS2 LABEL = (C=BLACK H=l.S A=90 R=O F=XSWISSB 
VALUE 
WIDTH 
MINOR 
'CUMMULATIVE AMOUNT OF N PERMEATED, MCG') 
(C=BLACK F=XSWISSB H=l) 
1 
NONE; 
FOOTNOTEl"SOURCE: DATASET: &&SOURCE BY PROGRAM: &&PROGRAM"; 
FOOTNOTE2 J=L H=l F=COMPLEX C=BLACK 
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'MEMBRANE SURFACE AREA= 4.9 SQCM'; 
TITLE2 C=BLACK H=l.5 F=XSWISS 
'PERMEATION OF NIFEDIPINE FROM PG:OA:ET:DM SUSPENSIONS'; 
TITLE3"MACRO PLOT OUTPUT (TIME= &&LOWT TO &&HIGHT)"; 
TITLE4 
"FORMULATION &&V3&H ASSAYED BY&&Vl&H (SEE NOTEBOOK PAGE=&&V2&H)"; 
TITLES 
"DONOR =&&Cl&H=&&Xl&H &&C2&H=&&X2&H &&C3&H=&&X3&H &&C4&H=&&X4&H"; 
TITLE6" &&CS&H=&&XS&H &&C6&H=&&X6&H"; RUN; 
PROC GPLOT DATA = EXDATA&H; 
PLOT CUMAMT*TIHE=V4 
/ VREF = 15000 HAXIS = AXISl VAXIS = AXIS2; 
/* PLOT ADJCON*TIME='A' PRED*TIME='P' U95*TIME='U' L95*TIME='L' 
/ OVERLAY VPOS=32 HPOS=SO; 
PLOT RESID*TIME /VREF=O VPOS=18 HPOS=60; 
PLOT COOKD*TIME /VREF=O VPOS=18 HPOS=60; 
*/ 
%LET H=%EVAL(&H+l); 
\ENO; 
%MEND CREATEl; 
* NOW CONTROL EXECUTION FROM HERE WITH MACROS 
*; \ASCON; 
* \ASRESPON; 
*; %CREATE1; 
RUN; 
ENDSAS; 
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************************************************************ 
* PROGRAM: SIMPLEX SAS Al 
* FUNCTION: CALCULATE PHYSICOCHEMICAL PARAMETERS 
OF THE DONOR FORMULATIONS 
* AUTHOR: EMILIO SQUILLANTE 
* VALIDATED: 10/16/92 
***********************************************************; 
%GLOBAL LOWX2 LOWX3 HIGHX2 HIGHX3 VSIZE HSIZE; 
%LET HSIZE = 0; %LET VSIZE = 0; 
%LET LOWX2 = 9; %LET HIGHX2 11; 
%LET LOWX3 = 9; %LET HIGHX3 = 11; 
DATA COMPOS; 
MISSING Q; 
TITLEl"OUTPUT: SIMPLEX SAS Al (UNBALANCED DATA, NMAX=4)"; 
INPUT CODE $ Cl$ C2 $ C3 $ C4 $ Xl X2 X3 X4; 
Cards; 
N41.l PG OA ET DM 
N46.9 PG OA ET OM 
N63 PG OA ET OM 
N78.8 PG OA ET OM 
N85.l PG QA ET OM 
N87.4 PG QA ET OM 
N88.l PG QA ET OM 
N88.2 PG QA ET OM 
Nl2 PG OA ET OM 
Pl4 PG OA ET OM 
Pl4 PG QA ET OM 
N43.l PG DA ET OM 
M70 PGO PG OA ET OM 
M70-PG1 PG DA ET OM 
M70-PG2 PG QA ET OM 
M70-PG3 PG OA ET OM 
M70-PG4 PG OA ET OM 
M70-PG5 PG OA ET OM 
M85A Q Q Q OM 
M85B Q OA Q OM 
P5.6 PG OA ET OM 
PB.DA PG OA ET OM 
PlOET PG OA ET OM 
P21.l PG OA ET OM 
P21.2 PG OA ET OM 
P21.3 PG OA ET OM 
P21.4 PG OA ET OM 
P21.5 PG OA ET OM 
P21 . 6 PG OA ET OM 
P21.7 PG DA ET OM 
P21.8 PG DA ET OM 
P25.4 PG QA ET OM 
P25.5 PG QA ET OM 
P25.6 PG OA ET OM 
P27.l PG OA ET OM 
P27.2 PG OA ET OM 
P27.3 PG OA ET OM 
P27.5 PG OA ET OM 
P27.9 PG OA ET OM 
P28.3 PG QA ET OM 
P28.4 PG QA ET OM 
0 21 0 79 
0 7 0 93 
0 18 18 63 
21 8 7 61 
18 15 67 0 
100 0 0 0 
63 18 18 0 
72 7 21 0 
0 2 0 98 
60 7 33 0 
60 7 33 0 
90 10 0 0 
100 0 0 0 
20 0 0 80 
43 0 0 57 
70 0 0 30 
87 0 0 13 
95 0 0 5 
0 0 0 100 
0 5 0 95 
25 25 25 25 
0 100 0 0 
0 0 100 0 
72 10 7 10 
55 25 10 10 
55 10 25 10 
10 10 25 55 
10 10 10 70 
10 25 11 55 
14 36 36 15 
10 25 25 40 
79 10 1 10 
79 1 10 10 
79 10 10 1 
97 1 1 1 
88 1 1 10 
88 10 1 1 
88 1 10 1 
83.5 5.5 5.5 5.5 
30 10 10 50 
40 10 10 40 
136 
P28.S PG OA ET OM so 10 10 30 
P28.6 PG OA ET OM 60 10 10 20 
P28.9 PG OA ET OM 1 10 10 79 
P42.l PG OA ET OM 71 12.2 12.9 4 
P42.2 PG OA ET OM 71 12.2 12.9 4 
DATA CONSTANT; 
MISSING Q; 
INPUT CODE $ SOLUB DENSITY; 
Cards; 
N41.l 34.5 Q 
N46.9 Q Q 
N63 40.3 Q 
N78.8 73.1 Q 
NBS.l 66.0 Q 
N87.4 10.0 Q 
N88.l Q Q 
N88.2 Q Q 
Nl2 Q Q 
Pl4 8.41 Q 
N43.l 7.5 Q 
M70 PGO 10.0 Q 
M70-PG1 82.0 Q 
M70-PG2 58.0 Q 
M70-PG3 41.0 Q 
M70-PG4 19.0 Q 
M70-PGS 9 .2 Q 
MBSA 84 Q 
MBSB Q Q 
PS.6 19.10 0.9577 
PB.CA 0.33 0.895 
PlOET 26 0.7890 
Pl0.2 17.00 Q 
P21. l Q Q 
P21.2 Q Q 
P21.3 Q Q 
P21.4 43.30 1. 0677 
P21.S 35.00 1.1009 
P21.6 22 .75 1. 0133 
P21.7 11. 63 0.9221 
P21.8 19.61 0.9957 
P25.4 15.20 Q 
P25.S 23.27 1.0480 
P25.6 10.52 0.9738 
P27.l 8.88 1.0381 
P27 .2 18.11 1.0585 
P27.3 8.42 0.9671 
P27.5 9.41 Q 
P27 .9 14.04 0.9926 
P28.3 50.59 1.0664 
P28.4 43.39 1. 0522 
P28.S 35.77 1. 0348 
P28.6 27.07 1.0100 
P28.9 36.40 Q 
P42.l 11.37 0.9011 
' DATA RESULTS; 
MISSING Q; 
INPUT CODE $ @; 
DO I=l TO 4; INPUT SLOPE INCPT @ @; OUTPUT; END; 
CARDS; 
P21.l 58.33 -1 86.01 51.26 -111.92 18.24 -19.23 44.16 -1 35.90 
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11.60 36.86 10.57 47.21 22.07 -12 25 24.43 -22.77 
11.18 115.59 38.64 -78.42 18.34 -1.96 42.68 - 29.89 
4.26 -12.11 2.92 -7 .85 3.42 -4.67 Q Q 
P21.2 
P21.3 
P21.4 
P21.5 
P21.6 
P21. 7 
P21.8 
P25.4 
P25.5 
P25.6 
P5.6 
N41.l 
N46.9 
N63 
N78.8 
N85.l 
N87.4 
N88.l 
N88.2 
Pl4 
N43.l 
Pl0.2 
P8.0A 
M70 PGO 
M70-PG1 
M70-PG2 
M70-PG3 
M70-PG4 
M70-PG5 
M85A 
M858 
Nl2 
P27 .l 
P27.2 
P27.3 
P27 . 5 
P27.9 
P28.3 
P28 . 4 
P28.5 
P28.6 
P28.9 
P42.l 
P42.2 
PlOET 
3.18 -5.42 2.96 -5.22 3.41 -10.44 Q Q 
5.14 -16.73 7. 22 -22.09 22.52 -98.33 Q Q 
5.93 23.56 6.73 31.07 8.21 19.63 Q Q 
11.60 -30.62 14.27 -49 .57 15.88 -71.15 Q Q 
31.72 -74.39 32.50 -65.67 36.96 -94.81 Q Q 
26.63 -126.69 32.27 -155.2 30.31 -146.34 Q Q 
28.83 -30.59 28.83 -24.13 29.82 -7.18 Q Q 
31.15 -15 .89 33.91 -90.24 35.53 -129.94 38.25 -122.76 
2.1 23.20 2.45 32.60 1.60 18.8 2.67 27.90 
4.21 -39 .29 5.14 -46.01 4.68 -42.86 5.42 -39.20 
16 .27 -56.53 17.50 -66.50 12.33 -46.67 15.17 -45.17 
.89 -41 0.54 -0. 6 0.9 -1.0 1.71 -1.7 6 
Q Q Q Q Q Q Q Q 
3 3.8 0 3.0 Q Q Q Q 
8.25 11.57 8.32 14.54 10.06 3.71 Q Q 
4 .05 37.22 4.27 35.56 5.02 16 Q Q 
12.7 -5.6 11.33 -15.64 13.36 -16.24 Q Q 
13.2 -0 . 1 14.2 -0.1 13.4 -0.1 15 .2 -0.1 13.4 -9.2 0.889 -10 
19.2 62.1 14.3 62 17.l 54 16.5 55.1 
0.46 1.68 .22 2.17 0.245 1.92 Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
1.34 -12 1 .0 -10 0.9 -12 Q Q 
25.15 -103.7 33.46 -110 .2 33.49 -110.40 35.24 -152.96 
72.70 -558.0 80.88 -677.18 40.74 -331 .33 61.71 -377 .86 
20.92 -28.58 23.11 -50.43 23.96 -58.52 25.10 -49 .98 
29.3 -145 18.60 -82.71 37.64 -225.6 21.04 -107.16 
39.39 -173 20.58 -52.44 17.31 -30 .34 38.78 -169.22 
1.40 -4.72 1.89 -9.28 3.75 -15.12 1.59 -6.0 
43.76 -433 33.20 -314.89 33.91 -479.7 39.03 -566 
31.53 -172 94.8 -1295 48.32 -359 60.2 -828 
50.46 -235.8 Q Q 75.50 -441 .5 61.36 -300.1 
3.08 -8.70 2.98 -8 .04 Q Q Q Q 
17.67 -24.22 22.67 -66.04 21.12 -32 .4 21.15 -35 
9.95 18.65 9.01 60.22 7.4 29.6 9.5 47.78 
Q Q Q Q Q Q Q Q 
DATA CONC; 
MISSING Q; 
INPUT CODE $ @ 
DO I=l TO 4; INPUT Cl2H C24H @ @; OUTPUT; END; 
Cards; 
P21. l 487 610 455 565 186 255 360 441 
P21.2 173 244 171 256 235 303 263 362 
P21.3 248 313 349 450 202 260 249 250 
P21.4 40 230 28 98 101 186 Q Q 
P21.5 32 98 30 105 31 86 Q Q 
P21.6 50 148 71 174 81 184 Q Q 
P21. 7 91 135 108 161 115 175 Q Q 
P21. 8 101 142 117 160 121 199 Q Q 
P25.4 278 352 297 370 320 400 Q Q 
P25.5 193 286 230 322 Q 423 Q Q 
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P25.6 
P5.6 
N41.l 
N43.l 
N46.9 
N63 
N78.8 
N85.l 
N87.4 
NBB.l 
NBB.2 
PB.CA 
N43.l 
Pl0.2 
Pl4 
302 386 307 374 332 419 Q Q 
347.2 440.7 311 372 276 344 305 384 
50 95 38 71 62 108 60 105 
38 66.4 41 81.3 44 76.4 39 74.3 
16 64 20 80 28 92 17 72 
141 Q 107 Q 147 Q 132 Q 105 Q 
10.3 23.9 7.1 15.9 10 25.l 19 46 
5.1 7 . 4 4.3 5.4 4.2 5.2 Q Q 
Q Q Q Q Q Q Q Q 
107.8 159 109.9 147 117 . 4 155 Q Q 
71.4 102.5 79.7 108.5 88 114.4 Q Q 
6.9 12.2 4.79 12 .2 4.9 11 . 7 5.0 16 
Q Q Q Q Q Q Q Q 
19.2 62.l 14.3 62.0 Q Q Q Q 
143 Q 117 Q 140 Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
Q Q Q Q Q Q Q Q 
194.5 273.5 159 265 
M70 PGO 
M70-PG1 
M70-PG2 
M70-PG3 
M70-PG4 
M70-PG5 
M85A 
M85B 
Nl2 
P27.l 
P27.2 
P27.3 
P27.5 
P27.9 
P28.3 
P28.4 
P28.5 
P28.6 
P28.9 
P42.l 
P42.2 
279 353 275 408 
272 891 Q Q 78.3 354.l 335 870 
137 .2 203.4 220 340 
227 401.2 137 236 
306 519 181 265 
13.0 110 12 94 
10.2 371.4 65 477 
257 429 12 673 
358 412 456 612 
28 69 Q Q 
177 244 167 245 183 
134 180 164 213 108 
241 346 Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
269 182 261 
Q 141 181 
PROC SORT DATA=RESULTS; BY CODE; RUN; 
PROC SORT DATA=CONSTANT; BY CODE; RUN; 
PROC SORT DATA=COMPOS; BY CODE; RUN; 
PROC SORT DATA=CONC; BY CODE; RUN; 
DATA MERGED; MERGE COMPOS RESULTS CONC CONSTANT; BY CODE; 
DATA ALL; MISSING Q; *subsetting if stt to restrict formulations; 
SET MERGED; 
IF X2 > &LOWX2 AND X2 < &HIGHX2 AND X3 > &LOWX3 AND X3 < &HIGHX3; 
/*********************************************************** 
DHF 
IDMFS 
TIME 
OBSMFS 
R 
SPNIF 
SPSKIN 
DICTIONARY OF VARIABLES: 
Heat of formation of nifedipine by DSC (cal/mol). 
Ideal mole traction solubility determined by 
Hildebrand 's equation. 
Time that sample was taken (hours). 
Mole fraction solubility determined in the 
laboratory (mg/ml) . 
Gas constant. 
Solubility parameter of nifedipine from Fedor's 
method (cal/cm' ) 112 • 
Solubility parameter of porcine skin (cal/cm3 ) 1n. 
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SVPC = Theoretical skin:vehicle partition coeficient. 
SP1-SP4= Solubility parameter of propylene glycol, oleic 
acid, ethanol and dimethylisosorbide . (cal/c m3 ) 112 
TM Melting point of nifedipine (°K). 
To Normal body temperature ( ° K). 
TSP Total solubility parameter of donor vehicle. 
VM Molar volume of nifedipine estimated by Fedor's 
method (cm' /mol). 
***********************************************************/ 
MFXl=Xl/100; MFX2 =X2/100; MFX3=X3/100; MFX4=X4/100; 
SP1=14.00; SP2=7.91; SP3=12 . 55; SP4=9.02 ; 
MWPG = 76 . 10; MWOA = 28 2.45; MWET = 46.07; MWDM = 174.2; MWNIF 
346.34; 
DHF=9090; R=l.987; 
SPSKIN=20.0; 
SPNIF=l0 . 7; VM2=302.3; T0=298; TM=449; PHI=l; 
MOLNIF (SOLUB / 1000) / MWNIF; 
GMSOLTN DENSITY; 
GMSOLV GMSOLTN-(SOLUB/1000); 
MOLSOLV GMSOLV/(MWPG*MFXl+MWOA*MFX2+MWET*MFX3+MWDM*MFX4); 
OBSMFS MOLNIF/(MOLNIF+MOLSOLV); 
Vl MVPG*MFXl + MVOA*MFX2 + MVET*MFX3 + MVDM*MFX4; 
TSP MFXl*SPl+MFX2*SP2+MFX3*SP3+MFX4*SP4; 
DO WHILE (ITER > 0 . 0001); 
LSVPC = 
(((SPNIF-TSP)**2 - (SPNIF-SPSKIN)**2))*302.3/(2 . 3*1.98*310); 
SVPC lO**(LSVPC); ITER=0.9; 
A 
B 
LIMFS 
IMFS 
PHI 
ITER 
(DHF*(TM-TO))/(R*TO*TM); 
VM2*(PHI**2)*((SPNIF-TSP)**2)/(R*TO); 
(A+B); 
EXP( - LIMFS); 
(Vl*(l-IMFS))/(Vl*(l-IMFS)+(VM2*IMFS)); 
ITER - PHI; 
ENO; 
PCDEV 
FLUX 
(IMFS - OBSMFS) I OBSMFS; 
SLOPE • 17 I 4 . 9087; 
LAG 
DOSE 
PERMCOEF 
ENHFAC 
LABEL 
(-1) * INCPT / SLOPE; 
FLUX • 20 • 24 I 1000; 
FLUX I SOLUB; 
PROC 
1 
2 
3 
4 
5 
6 
7 
FLUX/2; *Assumes flux from pure PG = 2µg/h• cm2 ; 
IMFS 
OBSMFS 
FLUX 
SVPC 
PERMCOEF 
TSP 
Xl 
ENHFAC 
FORMAT; 
'P28.9 
'P21. 5 
'P28.3 
'P25.6 
'P28.4 
'P28.5 
' P28.6 
IDEAL MOLE FRACTION SOLUBLITY 
OBSERVED MOLE FRACTION SOLUBILITY 
NIFEDIPINE FLUX (UGM/SQCM*HR) 
SKIN:VEHICLE PARTITION COEFFICIENT 
PERMEABILITY COEFFICIENT 
TOTAL SOLUBILITY PARAMETER 
PERCENT PROPYLENE GLYCOL 
ENHANCEMENT FACTOR; 
VALUE FORM 
1 10 10 79' 
10 10 10 70' 
30 10 10 50' 
79 10 10 l ' 
40 10 10 40' 
50 10 10 30 ' 
60 10 10 20' 
SYMBOL! V= TRIANGLE I=STDM C=WHITE 
SYMBOL2 V= SQUARE I=STDM C=WHITE 
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SYMBOL3 V= STAR I=STDM C=WHITE 
SYMBOL4 V= x I=STDM C=WHITE 
SYMBOLS V= DIAMOND I=STDM C=WHITE 
SYMBOL6 V= HASH I=STDM C=WHITE 
SYMBOL? V= . I=STDM C=WHITE 
SYMBOLS V= I=STDM C=WHITE 
TITLE2"SORTED BY Xl X2 X3 X4 FLUX"; 
PROC SORT; BY Xl X2 X3 X4 FLUX; RUN; 
PROC PRINT; * NOOBS; 
VAR CODE Cl-C4 Xl-X4 Cl2H C24H FLUX LAG TSP SVPC IMFS OBSMFS PERMCOEF; 
PROC SORT DATA=ALL; BY CODE; 
PROC MEANS MAXDEC=4 NOPRINT; BY CODE; 
VAR Cl2H C24H FLUX LAG DOSE; 
OUTPUT OUT=PMEAN MEAN = MC12H MC24H MFLUX MLAG MOOSE 
STD = SC12H SC24H SFLUX SLAG SOOSE ; 
ID Xl-X4 TSP SVPC OBSMFS IMFS PCDEV PERMCOEF; 
TITLE2"SIMPLEX SAS PROC MEANS"; RUN; 
PROC SORT DATA=PMEAN OUT=PMEAN; BY MFLUX TSP ; RUN; 
PROC PRINT ROUND DATA=PMEAN; * NOOBS; 
VAR CODE Xl-X4 
MC12H SC12H MC24H SC24H MFLUX SFLUX MLAG SLAG MOOSE SOOSE 
TSP SVPC OBSMFS IMFS PCDEV; 
* ENDSAS; OPTIONS LS=80; 
PROC TABULATE F=4. ; CLASS CODE Cl C2 C3 C4 ; 
VAR Xl-X4 Cl2H C24H FLUX LAG TSP SVPC IMFS OBSMFS PERMCOEF; 
TABLE CODE *F=8. 
*F=8.2 IMFS*F=8 .2 OBSMFS*F=8.2 Cl2H*F=8.2 C24H*F=8.2 
LAG*F=S .2; 
ENDSAS; 
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TSP 
APPENDIX B: 
NUMERICAL AND STATISTICAL TECHNIQUES 
INTRODUCTION 
This appendix discusses the rationale behind the attainment of the following 
objectives: (1) identify the key independent variables which influence the problem and 
principle responses to be measured; (2) the fitting of some proposed model for the 
purpose of describing the shape of the response surface over the simplex factor space; 
and (3) determining the roles played by the individual components. Identification of 
the right blend of solvents which would allow adequate solubility, stability, 
permeability with minimal irritancy and lag time at a reasonable cost posed a 
challenge best solved by the use of appropriate statistical and mathematical tools. 
These objectives have been achieved through the use of mixture designs. A mixture 
design is performed by mixing together several ingredients. 6 Much of the 
introductory principles of mixture designs, models and the analysis of mixture data 
may be found primarily in the EXPERIMENTS WITH MIXTURES: Designs, 
Models, and the Analysis of Mixture Data7 from which this appendix draws heavily. 
In factorial experiments, the response varies depending on the actual amounts 
of each of the independent variables (i.e., "factors"). However, unlike factorial 
experiments, the distinguishing feature of a mixture design is that the independent, 
controllable factors represent proportionate amounts of the mixture rather than 
unrestrained amounts, the proportions of which must be nonnegative and sum to 
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unity. These restrictions limit the manner in which an investigator may: (1) choose 
the proportions of the ingredients; (2) analyze the data collected from experiments; 
and (3) interpret the results of the analysis. It is important that experiments be 
designed so that the independent variables of the system under investigation are 
perturbed in a controlled, deliberate manner so that observed effects can be properly 
attributed. For the factorial case, this generally means controlling the factor level 
combinations. This guideline is not easily applied to mixture problems because a 
change in one factor demands a commensurate change in the other factor(s). Using a 
compressed tablet as an example, if the final weight of the tablet were restricted to 
500mg, then a 10% decrease of binder would necessitate a 10% increase in some 
other component. It would not be possible to conclude whether change in the tablet's 
properties are attributable to the decrease in binder or the commensurate increase in 
other components of the tablet. To avoid this restriction on the factor level 
combinations, a possible alternative might have been to disperse the enhancers into an 
inert material (e.g., PEG) and allow the relative mole fraction of PG, OA, ET and 
DM to vary. This strategy assumes that the filler does not interact with the drug, 
skin or vehicles which often may not be justified and this approach is a less desirable 
one. While some materials are not believed to act directly to alter the permeability of 
stratum comeum lipid, indirect effects, such as alteration of skin hydration may be 
significant. Information regarding penetration enhancers generally focus on their 
presumed interaction with the epidermis. Our results suggest that a systematic 
investigation of these interactions between vehicle component and permeant offer the 
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key to explaining nifedipine permeation by comparing the molar ratio of system 
components to flux. 
The number of components is denoted by q and the proportion of the ilh 
component in the mixture is represented by X; , then 
xi ;,; 0, i = 1,2, ... ,q 
and 
(1) 
(2) 
Since our primary interest is to explain the permeation process from a molecular 
perspective, the proportionate amounts of mixture component is expressed in mole 
fraction terms rather than by volume or by weight. The two measured responses of 
interest (i .e., flux and lag time) are derived from the profiles obtained by plotting the 
steady state nifedipine permeation as a function of time. The flux is quantified from 
the slope and the lag time from the point of intersection with the abscissa of the back 
extrapolated portion of these curves. Due to practical considerations such as cost, 
irritancy and stability in order to form valid mixtures from which an acceptable 
formulation could be made, component i must be present in some minimum amount a; 
and maximum amount c,. In other words, the proportion X; of component i must be 
bounded below by a; > O and above by c,< 1.0. The quantity a, is known as the 
'lower bound', c, the 'upper bound ', and in addition to usual constraints , x, ~ 0, 
x, +x2+ . .. +x.= 1, a second limitation for the constrained simplex is 
O< a;Sx;SC; S l , i=l,2, ... ,q 
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To be effective the donor must contain relative proportions of the components 
restricted to the following upper, C;. and lower, a;, bounds: 
Comoonent Constraints 
Initial' 
10% < x, < 70% 
5% < X2 < 25% 
5% < X4 < 60% 
5% < X3 < 25% 
Refined' 
1% < x, < 97% 
1 % < X3 < 10% 
1 % < x2 < 10% 
1 % < X4 < 10% 
'Preliminary 'best-guess' estimates from literature. 
'Refined constraints determined from results of initial constraints. 
The experimental region or factor space of mixture experiments is different 
than that of factorial experiments. Mixture designs are referred to as a simplex 
designs because the experimental region of interest, defined by the values ascribed to 
X;. take on the shape of a simplex (i.e., "a regular figure of n + 1 vertices in n 
space"). In contrast, for a 2• factorial experiment, where x; take on the values of ± 
1, the factor space is a cuboidal, q·dimensional space. Thus, for a 24 factorial, this 
space is a tetrahedron while for a 24 mixture it is a pyramid. The experimental 
design space constitutes a polyhedron whose eight vertices (points l ·8) are based on 
the component restrictions mentioned above. The simplex coordinate system for q=3 
can be plotted on triangular graph paper; graphical representation of q > 3 is less 
straightforward. Three methods introduced for locating the vertices of a constrained 
region as well as for defining some of the centroids of the boundaries are the Saxena 
Nigram transformation8, the McLean Anderson9 algorithm and the XVERT algorithm 
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.·· 
developed by Snee and Marquardt10. For the present case, the vertices and face and 
total centroids are established with the extreme vertices algorithm. The 
two-dimensional faces are found by grouping the vertices of the polyhedron into 
groups of three of more vertices where each vertex has the same value x; for one of 
the components. The overall centroid, which is defined as the average of the eight 
vertices, is listed as point (9) . Taken together, the design points comprise the vertices 
and centroids of the faces, sides and edges of a convex polyhedron compatible with 
the requirements outlined by Snee" for fitting first-degree and quadratic models. The 
resulting factor space and the design point designations are presented in Figure 16. 
The dimensions of a {q,m} simplex-lattice must conform to the number of 
components (q) and the order (m) of the fitted model. The number of design points, 
n, is 
n = (q+m-1)1 
ml(q-l)l 
Therefore, a quadratic model fitted to the data obtained from the four-component 
formulations is designated a {4,2} simplex and requires at least ten well chosen 
(3) 
points, a cubic model a minimum of 20 points, and a quartic model 35 points. The 
number of terms in the canonical polynomials for these four component formulations 
would be 4, 10, 14, and 20 for a linear, quadratic, special cubic, and full cubic, 
respectively. These requirements are enumerated here to illustrate how rapidly such 
designs can escalate. Obviously, a compromise must be struck between accurate 
modeling of nifedipine permeation and restricting the study to manageable 
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proportions. This investigation utilized a {4,2} design to delimit the study, so that 
useful results could be obtained with the time and funds available. which is the special 
simplex-centroid model of equation (6) when q =4. In trying to decide on the 
particular form of the Scheffe's-type canonical polynomial model to be fitted to data 
collected at the points of a q =4 simplex-centroid design, it is noted that the special 
cubic model or simplex-centroid model of equation (6) is chosen over the 
lower-degree models because the terms in the special cubic model not only provide a 
measure of each pure blend, but provide measures of the binary and ternary blends. 
Rather than sequentially build the model by starting with the first-degree polynomial 
and work towards the special cubic model, we began with the complete special cubic 
model fitted to the data and work backward by testing the usefulness of the cubic 
term, the quadratic term, the crossproduct terms and finally the similarity of the linear 
terms in the model. The test statistics are those discussed by Marquardt and Snee 
(1974) Consequently, the following questions are posed: 
I. Is the flux and lag time response surfaces likely to be planar over the experimental 
space or are combinations of cosolvents likely to cause departures from linearity in 
the surface shape? If the blending of multiple-components is not additive, which 
pairs are likely to have synergistic or antagonistic effects? Are complete (quaternary) 
blends likely to have more desirable responses than ternary , binary or even pure 
blends? Also, if we assume the relationship between components is linear, should the 
permeation results be collected at vertices of the pyramid only, or should we use 
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complete mixtures that are very close to the vertices? Furthermore, even if the 
relationship is linear, should midledge or interior points be collected to check the 
assumption of linearity? 
2. If the simplex arrangement chosen for the distinct possibility that the surface is not 
planar, should additional observations be collected at interior points of the polyhedron 
for the purpose of checking the fit inside the triangle? If so, is the centroid of the 
triangle the location at which to sample the interior? 
3. Are there combinations which yield acceptable flux and lag times? (An a=ptable 
flux must exceed 30 mcg/h•cm2 and an acceptable lag time must not exceed 4 hours) 
Initially it is assumed that there exists some fundamental relationship 
(4) 
which describes the dependence of the response on the proportions, x1, x2,. •• , x. of 
the components. The response function in equation (4) is expressible as a low-degree 
polynomial such as the first-degree polynomial 
(5) 
or the second degree polynomial 
(6) 
Besides the difference in their experimental regions, mixture experiments differ from 
the ordinary regression problems in the form of the polynomial. The canonical form 
is derived by applying to equation (4) the restriction {x, + x2 ••• + x. = 1.0} to the 
terms of the standard polynomial and simplifying. The reparamatized forms of these 
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general polynomials are used because the x;'s are constrained to sum to one and 
standard computer regression programs cannot be used for fitting the models when the 
x;'s sum to unity without creating problems in the calculations. 
Terms of higher degree must be added to account for curvature in one or more 
directions. Quadratic and cubic models with interaction terms was employed. As 
mentioned previously, the number of terms and thus the number of coefficients 
increases rapidly with increasing number of factors and increasing order, but 
fortunately interactions between more than two factors in practice are seldom 
significant. For the quaternary systems, the number of coefficients required in the 
polynomial model would be 5, 15 and 35 for a first, second and third degree 
polynomial, respectively. Polynomial models are not the only model when theoretical 
grounds suggest another model would be plausible, e.g. , a nonlinear model. 
A polynomial of fairly high degree would usually be needed to represent the 
response surface adequately over the whole experimental region and would require an 
excessive number of experiments. However, it is difficult to translate the physical 
meaning of quadratic or cubed effects, subsequent permeation experiments (i.e. , 
Design ll) were designed so that: (l) complete mixtures be used that are close to the 
vertices and (2) midledge or interior points be collected to check the assumption of 
linearity. Midledge observations are advantageous in the sense that if a second 
degree model is required, the estimates of the coefficients will have smaller variances 
than if interior points were used to estimate the {3's. Inclusion of interior points might 
be of greater benefit in characterizing synergism among components since interior 
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points represent complete blends consisting of all the components simultaneously 
whereas the edge or boundary points consist of binary mixtures. These observations 
gave rise to Design II, in which the upper constraint on oleic acid and ethanol was 
decreased to 10% mole fraction. 
For the final optimization studies, cosolvent blends were formulated by 
weighing propylene glycol (x1), cis-oleic acid (x,), ethanol (x3), and dimethyl 
isosorbide (x.,). Another property of the mixture problem is that the measured 
response is assumed to depend only on the proportions of the ingredients present in 
mixture and does not depend on the amount of the mixture. This assumption does not 
appear to hold and for this reason, the same amount (i.e., moles) of donor were used 
on all cells. Thus, equimolar doses were applied to the membrane surfaces and the 
penetration of nifedipine as a function of time was determined, the flux and lag times 
determined, and the unknown coefficients in the model are determined by the method 
of least squares. The coefficient estimates are then substituted into the model for use 
in predicting response values. 
Data analysis - Experimental design and analysis is performed using the ADX menu 
system of SAS/QC, SAS/STAT and SAS/GRAPH software. Although the factors are 
only observed at a finite number of values, the factors are treated as continuous 
variables. Using the ranges of each factor, we interpolate over their composite range 
in order to optimize the responses. 
RESULTS 
The functional form of equation (6) of the relationship between the responses 
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(flux and lag time) and the factors are given in Table XIII on page 110. The results of 
a ridge analysis are used to locate the optimum response within the design space 
(Table XV). This technique computes the estimated ridge of optimum responses for 
increasing radii from the center of the original design. The optimum values start at 
the center point and follow the path of steepest descent of ascent, respectively until 
within the region of experimentation the expected maximum and minimum are found. 
These results suggest that a relatively high level of PG and low levels of OA, 
ET and DM will give maximum flux and minimum lag times. Note, however, that 
the standard error increases as the optimum response ridge moves away from the 
center point of the design and toward the boundary of the design space, indicating that 
predictions near the edge are inherently less reliable. 
The ridge analysis output is only a list of numbers; to better understand it, 
consider a plot of the ridge values superimposed on the factor-response profile plot 
for each factor . Each profile plot is simply a scatter plot of one factor's values 
against response predictions made over the entire region of experimentation. A 
profile plot thus shows the relationship of the factor to the response, as well as giving 
an indication of interactions with other factors. Superimposing the ridge analysis 
gives an indication of the movement and flow of the optimal response ridge over the 
multidimensional response surface. When sorted, it becomes obvious that the two 
objectives, maximizing flux while minimizing flux, conflict with one another. One 
solution is to set constraints on lag time that it lie below and to optimize flux subject 
to this constraint. Algorithms are available that permit several responses to be 
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simultaneously analyzed to identify mixtures that strike compromises between 
maximization of some response (e.g. flux) and minimization of another (e.g. lag 
time). 12 This useful feature is also incorporated into the SAS ADX menu system. 
It is not possible to picture response surfaces of a cubic model because they 
are hyperplanes in four-dimensional space. The eigenvalues provide additional 
information about the sensitivity of the stationary point to deviations from the 
optimum. The relative magnitude of the eigenvalues indicate the relative rate of 
change for each of the canonical direction w;. Those with the largest magnitude 
change quickest and it is these directions that are the most sensitive to deviation from 
the actual stationary point. The smaller eigenvalues indicate direction of lesser 
sensitivity. Unequal eigenvalues suggests that the behavior of the response function 
results in contours that are elliptical . The major axis belongs to the least sensitive 
direction (given by an eigenvector) and the minor axis is that of the greater 
eigenvalue. This ridge analysis provides further knowledge about which directions 
must be estimated most precisely and which are less important. 
The crossproduct coefficient estimates (the {Jijs) measure curvilinear departure 
from a hypothetically planar response surface. The synergistic blending of OA 
appears to be real since all fJ ;; for i =j =2 terms are greater than zero. Synergism 
among the other components may not be real, since {J" is not significantly greater than 
zero based on the comparison of each coefficient estimate to the value of its standard 
error in the form of an approximate Student's I-statistic and then comparing each 
computed value oft to the tabled value t15,0_25 The sign of the {J's and the 
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corresponding value of the t-statistic lead us to infer that the individual terms are 
antagonistic toward one another in overall formulation performance while 
combinations of factor 2 (i.e., oleic acid) strongly interacts with all three factors . 
Furthermore, the magnitude of the interaction terms are large and probably represents 
the driving force for enhanced permeability in these systems. 
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APPENDIX C: 
PROTOTYPE TRANSDERMAL DEVICE DESIGN 
INTRODUCTION - The effect of adhesive composition on TDS performance is well 
recognized. In previous studies, we have investigated the role of solubility and the 
influence of formulation components and permeation enhancers on the skin 
permeability of the very hydrophobic calcium channel blocker nifedipine. Rate and 
extent of nifedipine permeation was enhanced in vitro by the judicious choice of 
donor solvent vehicle composition. The total amount of drug absorbed, Q, was found 
to be directly related to the volume of propylene glycol (PG), ethanol (ET) and 
dimethyl isosorbide (DM). The literature has noted that ET' and PG2 are well 
absorbed when applied topically and our work has demonstrated that the permeation 
of nifedipine may be linked to the presence of these cosolvents in our formulations. 
Investigations such as those performed by Lin3 demonstrate that cosolvent levels are 
likely to significantly affect the mechanical properties of the device, especially at the 
skin:device interface. Preliminary results have shown that the delivery of clinically 
useful amounts of nifedipine may require relatively large amounts of solvent at the 
skin-device interface. This report examines the effect of two donor formulations on 
the adhesive properties and drug release from a variety of pressure sensitive adhesive 
(PSA) films. 
Frequently, the fabrication of PSA's require heat to assist crosslinking and to 
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drive off residual solvent.4 The deleterious effect of high temperatures required by 
solvent-based and hot-melt coating processes pose Hmitations on the selection of 
enhancers such that avoidance of a heating step would be useful. Low temperature 
curing of silicone rubber to prepare a monolithic TDS would be particularly useful 
when enhancers of low vapor pressure are incorporated into the formulation . This 
study evaluates silicone elastomer matrices containing drug and penetration enhancer 
fabricated by polymerizing silicone precursors at room temperature. Alternatively, 
steps that require processing at elevated temperatures may be executed prior to the 
addition of heat-sensitive components. This was accomplished by the formation of 
PSA films and their subsequent lamination , at room temperature, to a layer 
incorporating the drug and enhancers. Matrix and reservoir-type devices thus formed 
are evaluated to deliver drug and enhancer to the skin. 
EXPERIMENTAL - All materials were gifts of the respective companies unless 
noted otherwise and were used as received. Ethanol, isopropyl myristate, nifedipine, 
oleic acid and propylene glycol were purchased from Sigma Chemical Co. St Louis, 
MO 63178. Arone (Whitby Research, 2801 Reserve Street, Richmond, VA 23261), 
dimethyl isosorbide (IC! Specialty Chemicals, Wilmington, DE 19897) , ethylene vinyl 
acetate (EVA) from 3M and silicones from Dow-Coming were gifts. The cosolvent 
vehicle was composed of oleic acid , ethanol, and propylene glycol (mole fraction per 
cent 1 :2:7) . Stock drug:enhancer suspensions (10% excess nifedipine) were prepared 
for subsequent manufacture of devices. 
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Polymers and resins - The polymer substrates, being dispersions of monomers in a 
volatile carrier, are expressed in terms of weight of solids. The monolithic silicone 
rubber-enhancer-drug matrix (SE) consisted of a two part 360:382 Silicone Medical 
Fluid and a Silastic MDX4-4210 Medical Grade Elastomer (Dow Coming Corp., 
2020 Willard H. Dow Center Midland, MI 48674). The pressure sensitive adhesives 
(PSA) evaluated were: (1) silicone (SA) X7-4301 and X7-2920 (Dow Corning); (2) 
polystyrene-block-polyisoprene-block-polystyrene (PIB) of 15:85 styrene/rubber ratio 
(Shell Schweiz AG, CH Zurich); (3) polyacrylic DURO-TAK 120-1753 (PA) 
crosslinked with 4 % w/w aluminum acetyl acetonitrile (National Starch and Chemical 
Company Bridgewater, NJ); and (4) ethyl :vinyl acetate hot melt (EVA) 
(33:400128:800). The hot-melt mixtures were modified with Hercules C, Abitol and 
Cetiosol S (Scheller AG, CH-Zurich) and heated to 70-80 °C. 
Monolithic matrix preparation - The monolithic silicone devices were prepared from 
the 360:382 Medical Fluids or the Silastic MDX4-4210 silicone elastomer by 
thoroughly mixing one part of curing agent with 10 parts by weight of the base 
elastomer. After five minutes of blending in a rotary mixer (Electrocraft Co. 1600 
Second Street Hopkins, MI) the desired weight percent of drug and enhancer are 
added incrementally to the silicone mixture. The mixture is then drawn up into a 20 
ml syringe and cured for 72 hours at room temperature to permit complexation and 
crosslinking. The cured polymeric cylinder is sliced into 0.5 cm thick slices. 
PSA film preparation - The stock liquid drug:enhancer mixtures were added 
incrementally to the liquid PSA's in a ratios of 1:1:8, mixed for 10 minutes and then 
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applied to polyester (PE) backing layers (3M Company). The films were prepared in 
thicknesses of 50 and 200 microns in a suspended-knife apparatus. Removal of 
residual solvent was accomplished by evaporation in a ventilated oven set at 60 °C for 
20 minutes. The films were then laminated onto a foil release liner and stored under 
ambient conditions. 
Reservoir device preparation - Polypropylene (PP) membrane of 38% porosity 
(Celgard 2400 Celanese Separations Products Box 32414, Charlotte, N.C. 28232) was 
investigated as retaining membrane. Scotchpack heatsealable, polyester (PE) film 
laminate (No. 1022 3M Company) comprised the backing layer. Silicone PSA films 
were applied to the release liner (PE film No.9747, 3M Company) , a layer of Celgard 
placed atop the PSA and the backing layer placed atop the Celgard layer. The 
laminate thus formed was heat sealed using a die compressed for 13 seconds at 70 °C 
to form a patch with a reservoir between the Celgard and backing layer (see 
Figure 27). The patch reservoir was loaded by inserting a hypodermic syringe into 
the orifice leading into the reservoir chamber, expressing 0.3 ml of the stock 
drug:cosolvent mixtures containing 10% excess nifedipine into the chamber and heat 
sealing the orifice. Patches were stored for one week prior to testing to allow the 
reservoir components to equiJjbrate with the PSA. 
Partioning studies - An equilibrium method5 was used to determine the 
membrane-vehicle partition coefficient. Medical grade silicone adhesive was cast into 
membranes, ground into small pieces, weighed and placed into screw top test tubes. 
A known volume of 0.01 molar phosphate buffered nifedipine solutions was added to 
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Figure 27. Schematic of prototype resevoir transdermal delivery system. 
each tube and placed in a shaker bath held at 37°C for 2 weeks. For each sample 
vehicle studied, several tubes were prepared, samples were withdrawn at daily 
intervals, and the resulting concentrations were determined. For all cases, 
equilibrium was reached within 5 days as evidenced by no further decrease in the 
solution concentration. The partition coefficient was calculated from the change in 
the nifedipine concentration of the solutions before and after the partition. The 
concentration of the drug was measured by HPLC. For the purpose of calculation, 
the density of the dimethylsiloxane was assumed to be unity, which is a reasonable 
approximation. 6 The partition coefficient was calculated by dividing the membrane 
solubility by the saturation solubility in the solvent system under consideration. Total 
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amount recoverable was determined by placing membranes in 30 ml scintillation vials 
and agitated at 30 oscillations per minute at 37°C. The fluid in the vials was 
replaced until no more nifedipine was detected. 
Kinetic studies - Screening of PSA films were carried out by measurement of 
penetration rates through freshly excised hairless mouse skins mounted in Franz cells 
to measure their usefulness as delivery devices. The laminates were placed on the 
excised skin, a 200 gram weight placed atop for 2 minutes, and then mounted in the 
Franz cell. 
RFSULTS - The physical properties of the films studied and permeation of nifedipine 
through the materials tested in this initial screening are shown in Table XVI. No 
decomposition of nifedipine could be detected by HPLC, suggesting that the patch 
components were resistant to oxidation and did not need stabilizing additives often 
necessary in many organic-based PSAs. In addition to the numerous advantages 
reported for silicone-based devices,7·s.t.9 the silicone PSA tested appears to retain a 
suitable degree of tack for initial bonding, conformance to skin contours and 
accommodation of skin movement needed to hold the TDS in place for several days, 
sufficient cohesive strength is observed leaving no residue when removed. 
Physical compatibility when measured by the 180 degree peel test showed the 
adhesive strength of the 200µ films were affected in the following order: SISPSA < 
SPSA < PPSA < HMPSA. The results in Table XVI show good physical stability 
in silicone PSA. To our knowledge, there is but one report evaluating nifedipine:PSA 
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Table XVI. Properties of acrylic, rubber-based and silicone matrix and pressure 
sensitive adhesives. 
POLYMER Tack Peel 
DURO-TAK 120-1753 high high 
Ethylene vinyl acetate low low 
PIB 15:85 medium medium 
Silicone Matrix 360:382 none none 
Silicone elastomer high medium 
X7-4301 
compatibility and this was performed at a I% loading level. 10 Best performance was 
obtained from a TDS design composed of four basic components: an impermeable 
backing, an adhesive, a drug reservoir, and microporous membrane to contain the 
drug suspended in vehicle. The amount of nifedipine permeated as a function of time 
for the silicone reservoir device is shown in Figure 28. These results demonstrate 
that, in terms of nifedipine permeation rates and physical properties, silicone is the 
best choice of the PSA's examined. The range of drugs that may be formulated as 
TDS's, particularly drugs whose permeation profiles are linked to the codiffusion of 
vehicle, may be extended by the adoption of reservoir-type designs. 
In summary, the in-vitro skin permeation profiles of nifedipine (N) under the 
influence of selected penetration enhancers from adhesive matrix devices was 
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evaluated using excised hairless mouse skin . Prototype devices containing 
permeation enhancers were prepared from silicone adhesives, silicone elastomer, 
pressure sensitive acrylic, and PIB pressure sensitive adhesives (PSA). Release from 
thin fLlms of these materials applied directly to the skin was poor. Fluxes were 
substantially higher when the drug:cosolvent mixture was fabricated as a reservoir 
system. 
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APPENDIX D 
CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK 
The ultimate goal of this type of research is not restricted to merely 
overcoming the formidable barrier posed by the skin but rather is an attempt to avoid 
the empirical approach in favor of quantitative, scientific tactics. We have achieved 
the former and made significant progress with the latter. Admittedly, extrapolation of 
the results of our inquiries to other systems is a dangerous exercise. More often than 
not, conclusions are merely assumptions to be tentatively entertained . Yet the 
decision process behind the choice of the enhancer-solvent combinations for other 
hydrophobic penetrants having different physicochemical properties is a topic worthy 
of further consideration. If our hypotheses regarding the crucial effect of 
solubilization within the epidermal layers is correct and if our observations were 
mirrored by other permeants, inferences made early in the development process 
regarding TDS design could be justified. 
Foremost in our minds at this time is the disposition of non-drug components 
that constitute the donor. The data presented constitutes a strong case for a 
hypothetical linkage of solvent permeation with drug permeation and their 
measurement holds the key to the interpretation of the information we have gathered. 
Furthermore, measurements should be conducted to determine skin uptake of 
enhancers e.g., oleic acid because it may be that enhancer skin uptake, hence 
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penetration enhancement, is dependent on thermodynamic activity of the oleic acid in 
vehicle rather than that of the drug. Sheets of epidermis, including the horny layer, 
may be separated from the underlying dermis and mounted in diffusion cells so that 
the diffusion and preferential uptake of compounds may be followed. Future work 
might utilize these techniques in the hope of correlating flux through intact skin to 
flux through the perturbed membrane, thus identifying the site of control. 
The techniques used in this thesis were subject to constraints imposed by 
equipment; alternative strategies could have been employed to examine the effect of 
cosolvent composition on permeation. Although we employed an infinite dose design 
with regard to drug, the results clearly display a dependence of permeation on the 
molar amount of cosolvent applied and future work might take this into consideration. 
Radiolabeled drug and cosolvent would permit direct quantitation. Unfortunately, 
radiolabeled nifedipine and dimethylisosorbide were unavailable for use in these 
experiments; methods that permit direct quantitative measurements of drug and 
enhancer in the skin compartment should be considered. The potential of 
microdialysis, a new bioanalytical sampling technique that permits dermal flux of 
topically applied compounds to be monitored directly, has proved to be a powerful 
technique in the characterization of dermal transport of 5-FU .1 
Finally, a need exists to develop methods to predict the in vivo performance of 
TDSs. Such methods would be invaluable in engineering new systems. As we 
increase our understanding of how dosage form components interact with the skin we 
likewise increase our proximity to this elusive goal . 
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